1
|
Rodríguez CL, Strub C, Fontana A, Verheecke-Vaessen C, Durand N, Beugré C, Guehi T, Medina A, Schorr-Galindo S. Biocontrol activities of yeasts or lactic acid bacteria isolated from Robusta coffee against Aspergillus carbonarius growth and ochratoxin A production in vitro. Int J Food Microbiol 2024; 415:110638. [PMID: 38430685 DOI: 10.1016/j.ijfoodmicro.2024.110638] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2023] [Revised: 02/09/2024] [Accepted: 02/21/2024] [Indexed: 03/05/2024]
Abstract
Biocontrol Agents (BCAs) can be an eco-friendly alternative to fungicides to reduce the contamination with mycotoxigenic fungi on coffee. In the present study, different strains of bacteria and yeasts were isolated from Ivorian Robusta coffee. Their ability to reduce fungal growth and Ochratoxin A (OTA) production during their confrontation against Aspergillus carbonarius was screened on solid media. Some strains were able to reduce growth and OTA production by 85 % and 90 % and were molecularly identified as two yeasts, Rhodosporidiobolus ruineniae and Meyerozyma caribbica. Subsequent tests on liquid media with A. carbonarius or solely with OTA revealed adhesion of R. ruineniae to the mycelium of A. carbonarius through Scanning Electron Microscopy, and an OTA adsorption efficiency of 50 %. For M. caribbica potential degradation of OTA after 24 h incubation was observed. Both yeasts could be potential BCAs good candidates for Ivorian Robusta coffee protection against A. carbonarius and OTA contamination.
Collapse
Affiliation(s)
- Claudia López Rodríguez
- Qualisud, Univ Montpellier, CIRAD, Institut Agro, IRD, Avignon Univ, Univ de La Réunion, Montpellier, France; Applied Mycology Group, Environment and AgriFood Theme, Cranfield University, Cranfield, UK
| | - Caroline Strub
- Qualisud, Univ Montpellier, CIRAD, Institut Agro, IRD, Avignon Univ, Univ de La Réunion, Montpellier, France.
| | - Angélique Fontana
- Qualisud, Univ Montpellier, CIRAD, Institut Agro, IRD, Avignon Univ, Univ de La Réunion, Montpellier, France
| | | | - Noël Durand
- Qualisud, Univ Montpellier, CIRAD, Institut Agro, IRD, Avignon Univ, Univ de La Réunion, Montpellier, France; CIRAD, UMR Qualisud, F-34398 Montpellier, France
| | - Corinne Beugré
- Laboratory of Microbiology and Molecular Biology, Department of Food Science and Technology, University of Nangui Abrogoua, Abidjan, Cote d'Ivoire
| | - Tagro Guehi
- Laboratory of Microbiology and Molecular Biology, Department of Food Science and Technology, University of Nangui Abrogoua, Abidjan, Cote d'Ivoire
| | - Angel Medina
- Applied Mycology Group, Environment and AgriFood Theme, Cranfield University, Cranfield, UK
| | - Sabine Schorr-Galindo
- Qualisud, Univ Montpellier, CIRAD, Institut Agro, IRD, Avignon Univ, Univ de La Réunion, Montpellier, France
| |
Collapse
|
2
|
Al Riachy R, Strub C, Durand N, Chochois V, Lopez-Lauri F, Fontana A, Schorr-Galindo S. The Influence of Long-Term Storage on the Epiphytic Microbiome of Postharvest Apples and on Penicillium expansum Occurrence and Patulin Accumulation. Toxins (Basel) 2024; 16:102. [PMID: 38393181 PMCID: PMC10891703 DOI: 10.3390/toxins16020102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2023] [Revised: 01/31/2024] [Accepted: 02/04/2024] [Indexed: 02/25/2024] Open
Abstract
Patulin is a secondary metabolite primarily synthesized by the fungus Penicillium expansum, which is responsible for blue mold disease on apples. The latter are highly susceptible to fungal infection in the postharvest stages. Apples destined to produce compotes are processed throughout the year, which implies that long periods of storage are required under controlled atmospheres. P. expansum is capable of infecting apples throughout the whole process, and patulin can be detected in the end-product. In the present study, 455 apples (organically and conventionally grown), destined to produce compotes, of the variety "Golden Delicious" were sampled at multiple postharvest steps. The apple samples were analyzed for their patulin content and P. expansum was quantified using real-time PCR. The patulin results showed no significant differences between the two cultivation techniques; however, two critical control points were identified: the long-term storage and the deck storage of apples at ambient temperature before transport. Additionally, alterations in the epiphytic microbiota of both fungi and bacteria throughout various steps were investigated through the application of a metabarcoding approach. The alpha and beta diversity analysis highlighted the effect of long-term storage, causing an increase in the bacterial and fungal diversity on apples, and showed significant differences in the microbial communities during the different postharvest steps. The different network analyses demonstrated intra-species relationships. Multiple pairs of fungal and bacterial competitive relationships were observed. Positive interactions were also observed between P. expansum and multiple fungal and bacterial species. These network analyses provide a basis for further fungal and bacterial interaction analyses for fruit disease biocontrol.
Collapse
Affiliation(s)
- Reem Al Riachy
- Qualisud, Univ Montpellier, Univ d’Avignon, CIRAD, Institut Agro, IRD, Univ de La Réunion, Montpellier, France; (R.A.R.); (C.S.); (N.D.); (V.C.); (F.L.-L.); (A.F.)
| | - Caroline Strub
- Qualisud, Univ Montpellier, Univ d’Avignon, CIRAD, Institut Agro, IRD, Univ de La Réunion, Montpellier, France; (R.A.R.); (C.S.); (N.D.); (V.C.); (F.L.-L.); (A.F.)
| | - Noël Durand
- Qualisud, Univ Montpellier, Univ d’Avignon, CIRAD, Institut Agro, IRD, Univ de La Réunion, Montpellier, France; (R.A.R.); (C.S.); (N.D.); (V.C.); (F.L.-L.); (A.F.)
- CIRAD, UMR Qualisud, F-34398 Montpellier, France
| | - Vincent Chochois
- Qualisud, Univ Montpellier, Univ d’Avignon, CIRAD, Institut Agro, IRD, Univ de La Réunion, Montpellier, France; (R.A.R.); (C.S.); (N.D.); (V.C.); (F.L.-L.); (A.F.)
- CIRAD, UMR Qualisud, F-34398 Montpellier, France
| | - Félicie Lopez-Lauri
- Qualisud, Univ Montpellier, Univ d’Avignon, CIRAD, Institut Agro, IRD, Univ de La Réunion, Montpellier, France; (R.A.R.); (C.S.); (N.D.); (V.C.); (F.L.-L.); (A.F.)
| | - Angélique Fontana
- Qualisud, Univ Montpellier, Univ d’Avignon, CIRAD, Institut Agro, IRD, Univ de La Réunion, Montpellier, France; (R.A.R.); (C.S.); (N.D.); (V.C.); (F.L.-L.); (A.F.)
| | - Sabine Schorr-Galindo
- Qualisud, Univ Montpellier, Univ d’Avignon, CIRAD, Institut Agro, IRD, Univ de La Réunion, Montpellier, France; (R.A.R.); (C.S.); (N.D.); (V.C.); (F.L.-L.); (A.F.)
| |
Collapse
|
3
|
Dieye CAT, Durand N, Schorr-Galindo S, Strub C, Fontana A. Impacts of abiotic factors on the growth of three commercial biological control agents, on the growth and mycotoxinogenesis of Fusarium graminearum and on their interaction. J Sci Food Agric 2024; 104:932-941. [PMID: 37721389 DOI: 10.1002/jsfa.12991] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/19/2022] [Revised: 07/03/2023] [Accepted: 09/18/2023] [Indexed: 09/19/2023]
Abstract
BACKGROUND Evolving climatic conditions impact the behavior of microorganisms. The lack of efficiency of beneficial microorganisms against pathogens can be due to these evolving abiotic factors more favorable to the development and adaptation of pathogens. It is therefore of great interest to understand their impact (especially temperature increase and relative humidity (RH) variation) on pathogenic and non-pathogenic microorganisms. This work aimed to examine the possible effects of increasing temperature (20, 25, 30 and 33 °C) and RH (40%, 50%, 60% and 80%) on the growth and mycotoxin production (deoxynivalenol (DON) and zearalenone (ZEN)) of Fusarium graminearum, on the growth of three commercial biocontrol agents (BCAs; Mycostop®, Xedavir® and Polyversum®) and on the pathogen-BCA interaction. RESULTS Results demonstrated that BCAs have contrasting impacts on the growth and mycotoxinogenesis of F. graminearum depending on abiotic factors. At 25 °C and regardless of RH, commercial BCAs limit DON production by F. graminearum, but at 30 °C and intermediate RH, Xedavir® is no longer effective. The ability of Xedavir® to control the production of ZEN production by F. graminearum is also affected by abiotic factors. However, increasing temperature has an opposite effect on its ability to control the accumulation of ZEN. Polyversum® oomycete is the BCA with the most resilient efficacy against F. graminearum toxinogenesis under the different abiotic factors. CONCLUSION This work provides new knowledge of the effect of these abiotic parameters on the interaction between BCA and F. graminearum, especially on the production of mycotoxins. It paves the way for the development of efficient and resilient mycotoxin biocontrol strategies using beneficial microorganisms against F. graminearum, thus contributing to global food security. © 2023 Society of Chemical Industry.
Collapse
Affiliation(s)
- Cheikh Ahmeth Tidiane Dieye
- UMR Qualisud, Univ Montpellier, Univ Avignon, CIRAD, Institut Agro, IRD, Univ de la Réunion, Montpellier, France
| | - Noël Durand
- UMR Qualisud, Univ Montpellier, Univ Avignon, CIRAD, Institut Agro, IRD, Univ de la Réunion, Montpellier, France
- CIRAD, UMR Qualisud, France - Qualisud, Univ Montpellier, Univ Avignon, CIRAD, Institut Agro, IRD, Univ de La Réunion, Montpellier, France
- Qualisud, Univ Montpellier, Univ Avignon, CIRAD, Institut Agro, IRD, Univ de La Réunion, Montpellier, France
| | - Sabine Schorr-Galindo
- UMR Qualisud, Univ Montpellier, Univ Avignon, CIRAD, Institut Agro, IRD, Univ de la Réunion, Montpellier, France
| | - Caroline Strub
- UMR Qualisud, Univ Montpellier, Univ Avignon, CIRAD, Institut Agro, IRD, Univ de la Réunion, Montpellier, France
| | - Angélique Fontana
- UMR Qualisud, Univ Montpellier, Univ Avignon, CIRAD, Institut Agro, IRD, Univ de la Réunion, Montpellier, France
| |
Collapse
|
4
|
Trevisan B, Pepe FF, Vallini I, Montagna E, Amoroso D, Berardi R, Butera A, Cagossi K, Cavanna L, Ciccarese M, Cinieri S, Cretella E, De Conciliis E, Febbraro A, Ferraù F, Ferzi A, Baldelli A, Fontana A, Gambaro AR, Garrone O, Gebbia V, Generali D, Gianni L, Giovanardi F, Grassadonia A, Leonardi V, Sarti S, Musolino A, Nicolini M, Putzu C, Riccardi F, Santini D, Sarobba MG, Schintu MG, Scognamiglio G, Spadaro P, Taverniti C, Toniolo D, Tralongo P, Turletti A, Valenza R, Valerio MR, Vici P, Clivio L, Torri V, Cazzaniga ME. Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients. Sci Rep 2023; 13:12255. [PMID: 37507480 PMCID: PMC10382472 DOI: 10.1038/s41598-023-39386-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Accepted: 07/25/2023] [Indexed: 07/30/2023] Open
Abstract
Nowadays, treatment of metastatic breast cancer (MBC) has been enriched with novel therapeutical strategies. Metronomic chemotherapy (mCHT) is a continuous and frequent administration of chemotherapy at a lower dose and so whit less toxicity. Thus, this strategy could be attractive for elderly MBC patients. Aim of this analysis is to provide insights into mCHT's activity in a real-life setting of elderly MBC patients. Data of patients ≥ 75 years old included in VICTOR-6 study were analyzed. VICTOR-6 is a multicentre, Italian, retrospective study, which collected data on mCHT in MBC patients treated between 2011 and 2016. A total of 112 patients were included. At the beginning of mCHT, median age was 81 years (75-98) and in 33% of the patients mCHT was the first line choice. Overall Response Rate (ORR) and Disease Control Rate (DCR) were 27.9% and 79.3%, respectively. Median PFS ranged between 7.6 and 9.1 months, OS between 14.1 and 18.5 months. The most relevant toxicity was the hematological one (24.1%); severe toxicity (grade 3-4) ranged from 0.9% for skin toxicity up to 8% for hematologic one. This is a large study about mCHT in elderly MBC patients, providing insights to be further investigated in this subgroup of frail patients.
Collapse
Affiliation(s)
- B Trevisan
- Azienda Ospedaliera San Gerardo, Monza, Italy
| | - F F Pepe
- Azienda Ospedaliera San Gerardo, Monza, Italy
| | - I Vallini
- Ospedale di Circolo e Fondazione Macchi, Varese, Italy
| | - E Montagna
- European Institute of Oncology, Milan, Italy
| | | | - R Berardi
- Azienda Ospedaliera Universitaria Ospedali Riuniti, Torrette, Italy
| | - A Butera
- Nuovo Ospedale San Giovanni Di Dio, Florence, Italy
| | | | - L Cavanna
- Azienda Ospedaliera Piacenza, Piacenza, Italy
| | | | - S Cinieri
- Ospedale A. Perrino, Brindisi, Italy
| | | | | | - A Febbraro
- Ospedale S. Cuore di Gesù Fatebenefratelli, Benevento, Italy
| | - F Ferraù
- Ospedale San Vincenzo, Taormina, Italy
| | - A Ferzi
- Azienda Ospedaliera Ospedale Civile Di Legnano, Magenta, Italy
| | | | - A Fontana
- Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
| | | | - O Garrone
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - V Gebbia
- Ospedale La Maddalena, Palermo, Italy
| | - D Generali
- Istituti Ospitalieri Cremona, Cremona, Italy
| | | | | | | | | | - S Sarti
- IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
| | | | | | - C Putzu
- Azienda Ospedaliera-Universitaria, Sassari, Italy
| | - F Riccardi
- Ospedale Antonio Cardarelli, Naples, Italy
| | - D Santini
- Università Campus Bio-Medico, RomE, Italy
| | | | | | | | - P Spadaro
- Casa di Cura Villa Salus-Messina, Messina, Italy
| | | | | | | | | | | | - M R Valerio
- A.O.U. Policlinico Paolo Giaccone, Palermo, Italy
| | - P Vici
- INT Regina Elena, Rome, Italy
| | - L Clivio
- IRCCS Mario Negri Institute of Pharmacological Research, Milan, Italy
| | - V Torri
- IRCCS Mario Negri Institute of Pharmacological Research, Milan, Italy
| | | |
Collapse
|
5
|
Fontana A, Vinci G, Ronchi L, Mocchiutti A, Muscio G, Visentini P, Bassetti M, Novellino MD, Badino F, Musina G, Bonomi S. The largest prehistoric mound in Europe is the Bronze-Age Hill of Udine (Italy) and legend linked its origin to Attila the Hun. Sci Rep 2023; 13:8848. [PMID: 37258555 DOI: 10.1038/s41598-023-35175-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2023] [Accepted: 05/14/2023] [Indexed: 06/02/2023] Open
Abstract
Prehistoric monuments often constitute evident landmarks and sometimes, after falling into disuse, fascinated local people enough to stimulate speculations about their origin over time. According to legend, the Hill of Udine (NE Italy) was built by Attila the Hun's soldiers, but its origin (natural or anthropogenic) has been debated until now. Our research analyzed five new 40-m long stratigraphic cores, investigating for the first time the total thickness of the hill and compared the data with the available archaeological information. Moreover, we considered other hills and mounds in northern Italy and other European regions where folklore traditions relate their origin to Attila. The geoarchaeological and ethnographic data prove that the Hill of Udine is a Bronze Age anthropogenic mound erected between 1400 and 1150 BCE and that, later, folklore has transformed the ancestral memory of its origin into legend. By measuring 30 m in height and over 400,000 m3 in volume, the flat-topped hill is the largest prehistoric mound in Europe. This discovery reveals unprecedented skills in earth construction and confirms significant anthropogenic modifications of the environment during Bronze Age.
Collapse
Affiliation(s)
- A Fontana
- Department of Geosciences, University of Padova, Padua, Italy.
| | - G Vinci
- Department of Geosciences, University of Padova, Padua, Italy
- Department of History and Cultural Heritage, University of Siena, Siena, Italy
| | - L Ronchi
- Department of Geosciences, University of Padova, Padua, Italy
| | | | - G Muscio
- Museo Friulano di Storia Naturale, Comune di Udine, Udine, Italy
| | - P Visentini
- Museo Friulano di Storia Naturale, Comune di Udine, Udine, Italy
| | - M Bassetti
- Cora Società Archeologica Srl, Trento, Italy
| | - M D Novellino
- Department of Geosciences, University of Padova, Padua, Italy
- CNR-IGAG, Laboratory of Palinology and Paleoecology, Milan, Italy
| | - F Badino
- Department of Geosciences, University of Padova, Padua, Italy
- CNR-IGAG, Laboratory of Palinology and Paleoecology, Milan, Italy
| | - G Musina
- Soprintendenza Archeologia belle arti e paesaggio del Friuli Venezia Giulia, Trieste, Italy
| | - S Bonomi
- Soprintendenza Archeologia belle arti e paesaggio del Friuli Venezia Giulia, Trieste, Italy
| |
Collapse
|
6
|
Guzmán Penella S, Boulanger R, Maraval I, Kopp G, Corno M, Fontez B, Fontana A. Link between Flavor Perception and Volatile Compound Composition of Dark Chocolates Derived from Trinitario Cocoa Beans from Dominican Republic. Molecules 2023; 28:molecules28093805. [PMID: 37175215 PMCID: PMC10180179 DOI: 10.3390/molecules28093805] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2023] [Revised: 04/25/2023] [Accepted: 04/26/2023] [Indexed: 05/15/2023] Open
Abstract
The chemical composition of dark chocolate has a significant impact on its complex flavor profile. This study aims to investigate the relationship between the volatile chemical composition and perceived flavor of 54 dark chocolate samples made from Trinitario cocoa beans from the Dominican Republic. The samples were evaluated by a trained panel and analyzed using gas chromatography-mass spectrometry (GC-MS) to identify and quantify the volatile compounds. Predictive models based on a partial least squares regression (PLS) allowed the identification of key compounds for predicting individual sensory attributes. The models were most successful in classifying samples based on the intensity of bitterness and astringency, even though these attributes are mostly linked to non-volatile compounds. Acetaldehyde, dimethyl sulfide, and 2,3-butanediol were found to be key predictors for various sensory attributes, while propylene glycol diacetate was identified as a possible marker for red fruit aroma. The study highlights the potential of using volatile compounds to accurately predict chocolate flavor potential.
Collapse
Affiliation(s)
- Santiago Guzmán Penella
- CIRAD, UMR Qualisud, F-34398 Montpellier, France
- Qualisud, Univ Montpellier, Avignon Université, CIRAD, Institut Agro, IRD, Université de La Réunion, 97490 Montpellier, France
- Barry Callebaut AG, Hardturmstrasse 181, 8005 Zurich, Switzerland
| | - Renaud Boulanger
- CIRAD, UMR Qualisud, F-34398 Montpellier, France
- Qualisud, Univ Montpellier, Avignon Université, CIRAD, Institut Agro, IRD, Université de La Réunion, 97490 Montpellier, France
| | - Isabelle Maraval
- CIRAD, UMR Qualisud, F-34398 Montpellier, France
- Qualisud, Univ Montpellier, Avignon Université, CIRAD, Institut Agro, IRD, Université de La Réunion, 97490 Montpellier, France
| | - Gabi Kopp
- Barry Callebaut AG, Hardturmstrasse 181, 8005 Zurich, Switzerland
| | - Marcello Corno
- Barry Callebaut AG, Hardturmstrasse 181, 8005 Zurich, Switzerland
| | - Bénédicte Fontez
- MISTEA, Université Montpellier, INRAE, Institut Agro, 34060 Montpellier, France
| | - Angélique Fontana
- Qualisud, Univ Montpellier, Avignon Université, CIRAD, Institut Agro, IRD, Université de La Réunion, 97490 Montpellier, France
| |
Collapse
|
7
|
Kouassi ADD, Koné KM, Assi-Clair BJ, Lebrun M, Maraval I, Boulanger R, Fontana A, Guehi TS. Effect of spontaneous fermentation location on the fingerprint of volatile compound precursors of cocoa and the sensory perceptions of the end-chocolate. J Food Sci Technol 2022; 59:4466-4478. [PMID: 36193455 PMCID: PMC9525491 DOI: 10.1007/s13197-022-05526-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Revised: 09/28/2021] [Accepted: 01/10/2022] [Indexed: 05/27/2023]
Abstract
Cocoa pod-opening delay and bean fermentation promote the organoleptic quality of chocolate. The present research investigated the changes in the volatile fingerprint of cocoa harvested at a traditional plantation. Cocoa beans extracted from 2-days pod-opening delay were simultaneously fermented for 5 days using container and then sun-dried to 7-8% moisture content at five different locations: Akoupé, San Pedro, Soubré, Djekanou and Daloa. The aromatic analysis were done on cocoa using the HS-SPME-GC/MS technique. Professional panelists evaluated the sensory perceptions of the chocolate. The results shows that cocoa fermented in both Daloa and Soubré regions were differentiated by 2,3-butanediol while those processed in other regions presented highest acetoin content. However, fermented cocoa from Soubré region exhibited most amount of 2,3-butanediol, diacetate A whereas 2,3,5,6-tetramethylpyrazine differentiated those from Daloa region. Sensory properties of chocolate were not linked to the aromatic compound precursors profile of beans. The fermentation performed in San Pédro region promote both the generation of more desirable aromatic compounds of cocoa and sensory attributes of the finished chocolate. The fermentation location generates a greater differentiation of the volatile fingerprint of cocoa and the sensory perceptions of the finished chocolate.
Collapse
Affiliation(s)
- Ange Didier D. Kouassi
- Food Sciences and Technology Department, UFR-STA, Université Nangui Abrogoua, 02 Bp 801 Abidjan 02, Côte d’Ivoire
| | - Koumba M. Koné
- Food Sciences and Technology Department, UFR-STA, Université Nangui Abrogoua, 02 Bp 801 Abidjan 02, Côte d’Ivoire
| | - Brice J. Assi-Clair
- Food Sciences and Technology Department, UFR-STA, Université Nangui Abrogoua, 02 Bp 801 Abidjan 02, Côte d’Ivoire
| | - Marc Lebrun
- CIRAD, UMR Qualisud, TA B 96/16, 75 Av JF Breton, 34398 Montpellier cedex 5, France
- Qualisud, Univ Montpellier, CIRAD, Université d’Avignon, Université de la Réunion, Montpellier SupAgro, Montpellier, France
| | - Isabelle Maraval
- CIRAD, UMR Qualisud, TA B 96/16, 75 Av JF Breton, 34398 Montpellier cedex 5, France
- Qualisud, Univ Montpellier, CIRAD, Université d’Avignon, Université de la Réunion, Montpellier SupAgro, Montpellier, France
| | - Renaud Boulanger
- CIRAD, UMR Qualisud, TA B 96/16, 75 Av JF Breton, 34398 Montpellier cedex 5, France
- Qualisud, Univ Montpellier, CIRAD, Université d’Avignon, Université de la Réunion, Montpellier SupAgro, Montpellier, France
| | - Angélique Fontana
- CIRAD, UMR Qualisud, TA B 96/16, 75 Av JF Breton, 34398 Montpellier cedex 5, France
- Qualisud, Univ Montpellier, CIRAD, Université d’Avignon, Université de la Réunion, Montpellier SupAgro, Montpellier, France
| | - Tagro S. Guehi
- Food Sciences and Technology Department, UFR-STA, Université Nangui Abrogoua, 02 Bp 801 Abidjan 02, Côte d’Ivoire
| |
Collapse
|
8
|
Del Mastro L, Poggio F, Blondeaux E, De Placido S, Giuliano M, Forestieri V, De Laurentiis M, Gravina A, Bisagni G, Rimanti A, Turletti A, Nisticò C, Vaccaro A, Cognetti F, Fabi A, Gasparro S, Garrone O, Alicicco MG, Urracci Y, Mansutti M, Poletti P, Correale P, Bighin C, Puglisi F, Montemurro F, Colantuoni G, Lambertini M, Boni L, Venturini M, Abate A, Pastorino S, Canavese G, Vecchio C, Guenzi M, Lambertini M, Levaggi A, Giraudi S, Accortanzo V, Floris C, Aitini E, Fornari G, Miraglia S, Buonfanti G, Cherchi M, Petrelli F, Vaccaro A, Magnolfi E, Contu A, Labianca R, Parisi A, Basurto C, Cappuzzo F, Merlano M, Russo S, Mansutti M, Poletto E, Nardi M, Grasso D, Fontana A, Isa L, Comandè M, Cavanna L, Iacobelli S, Milani S, Mustacchi G, Venturini S, Scinto A, Sarobba M, Pugliese P, Bernardo A, Pavese I, Coccaro M, Massidda B, Ionta M, Nuzzo A, Laudadio L, Chiantera V, Dottori R, Barduagni M, Castiglione F, Ciardiello F, Tinessa V, Ficorella A, Moscetti L, Vallini I, Giardina G, Silva R, Montedoro M, Seles E, Morano F, Cruciani G, Adamo V, Pancotti A, Palmisani V, Ruggeri A, Cammilluzzi E, Carrozza F, D'Aprile M, Brunetti M, Gallotti P, Chiesa E, Testore F, D'Arco A, Ferro A, Jirillo A, Pezzoli M, Scambia G, Iacono C, Masullo P, Tomasello G, Gandini G, Zoboli A, Bottero C, Cazzaniga M, Genua G, Palazzo S, D'Amico M, Perrone D. Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial. Lancet Oncol 2022; 23:1571-1582. [DOI: 10.1016/s1470-2045(22)00632-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2022] [Revised: 10/06/2022] [Accepted: 10/07/2022] [Indexed: 11/11/2022]
|
9
|
Cucciniello L, Blondeaux E, Bighin C, Gasparro M, Russo S, Dri A, Pugliese P, Fontana A, Naso G, Ferzi A, Riccardi F, Sini V, Fabi A, Montemurro F, De Laurentiis M, Arpino G, Del Mastro L, Gerratana L, Puglisi F. 270P Defining clinico-pathological characteristics of HER2 positive metastatic breast cancer (MBC) patients experiencing radiologic complete response (rCR) in a nationwide real-world cohort. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1854] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
10
|
Giuffrida G, Crisafulli S, Ferraù F, Fontana A, Alessi Y, Calapai F, Ragonese M, Luxi N, Cannavò S, Trifirò G. Global Cushing's disease epidemiology: a systematic review and meta-analysis of observational studies. J Endocrinol Invest 2022; 45:1235-1246. [PMID: 35133616 DOI: 10.1007/s40618-022-01754-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/07/2021] [Accepted: 01/25/2022] [Indexed: 11/30/2022]
Abstract
PURPOSE Cushing's disease (CD), 70% of endogenous hypercortisolism cases, is a rare disease caused by adrenocorticotropic hormone (ACTH)-secreting pituitary adenomas. To date, no systematic reviews and meta-analyses on its global epidemiology have been published. We provide a systematic review and meta-analysis of CD global epidemiology, also evaluating the quality of study reporting for the identified studies. METHODS MEDLINE and EMBASE databases were searched for studies on CD epidemiology from inception until November 30th, 2020, including original observational studies in English about CD prevalence and/or incidence for well-defined geographic areas. Two reviewers independently extracted data and assessed reporting quality. CD prevalence/incidence pooled estimates were derived from a random-effects meta-analysis. Reporting quality was assessed using a STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) checklist adapted for observational studies on rare diseases, heterogeneity using the Cochran's Q-test and its derived measure of inconsistency (I2). RESULTS Thirteen studies were included. The pooled CD prevalence was 2.2 [95% CI 1.1-4.8] per 100,000, while the incidence rate was 0.24 [95% CI 0.15-0.33] per 100,000 person-years. For both parameters, considerable between-studies heterogeneity was found (I2 = 78.8% and 87.8%, respectively). The quality of study reporting was rated as medium for 11 (84.6%) studies and as low for 2 (15.4%). CONCLUSION Overall, our systematic meta-analysis demonstrated CD epidemiology to be similarly reported across different areas of the world, with some exceptions regarding regional differences or observation period intervals. Keeping into account the methodological differences between each paper, large-scale studies on CD epidemiology are warranted. Setting up national specific registries, based on standardized diagnostic and clinical parameters, with clearly defined selection and analysis criteria, and a strong cooperation between the scientific national societies for endocrinology is crucial to exclude other causes of variability (i.e. geographical differences due to other factors like (epi)genetic changes), and to support public health decision making.
Collapse
Affiliation(s)
- G Giuffrida
- Department of Human Pathology of Adulthood and Childhood "G. Barresi", University of Messina, Messina, Italy
| | - S Crisafulli
- Department of Medicine, University of Verona, Verona, Italy
| | - F Ferraù
- Department of Human Pathology of Adulthood and Childhood "G. Barresi", University of Messina, Messina, Italy.
- Endocrine Unit, University Hospital "G. Martino", Messina, Italy.
| | - A Fontana
- Unit of Biostatistics, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
| | - Y Alessi
- Endocrine Unit, University Hospital "G. Martino", Messina, Italy
| | - F Calapai
- Department of Chemical, Biological, Pharmaceutical, Environmental Sciences, University of Messina, Messina, Italy
| | - M Ragonese
- Department of Human Pathology of Adulthood and Childhood "G. Barresi", University of Messina, Messina, Italy
| | - N Luxi
- Department of Diagnostics and Public Health, University of Verona, Verona, Italy
| | - S Cannavò
- Department of Human Pathology of Adulthood and Childhood "G. Barresi", University of Messina, Messina, Italy
- Endocrine Unit, University Hospital "G. Martino", Messina, Italy
| | - G Trifirò
- Department of Diagnostics and Public Health, University of Verona, Verona, Italy
| |
Collapse
|
11
|
Del Re M, Omarini C, Diodati L, Palleschi M, Meattini I, Crucitta S, Lorenzini G, Isca C, Fontana A, Livi L, Piacentini F, Fogli S, De Giorgi U, Danesi R. Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open 2022; 7:100381. [PMID: 35131649 PMCID: PMC8897157 DOI: 10.1016/j.esmoop.2022.100381] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2022] [Accepted: 01/06/2022] [Indexed: 11/30/2022] Open
Affiliation(s)
- M Del Re
- Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
| | - C Omarini
- Division of Medical Oncology, University Hospital of Modena, Modena, Italy
| | - L Diodati
- Unit of Medical Oncology, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy
| | - M Palleschi
- Unit of Medical Oncology, IRCCS-Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy
| | - I Meattini
- Department of Experimental and Clinical Biomedical Sciences 'M. Serio', University of Florence, Florence, Italy; Radiation Oncology Unit - Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy
| | - S Crucitta
- Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - G Lorenzini
- Unit of Medical Oncology, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy
| | - C Isca
- Division of Medical Oncology, University Hospital of Modena, Modena, Italy
| | - A Fontana
- Unit of Medical Oncology, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy
| | - L Livi
- Department of Experimental and Clinical Biomedical Sciences 'M. Serio', University of Florence, Florence, Italy; Radiation Oncology Unit - Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy
| | - F Piacentini
- Division of Medical Oncology, University Hospital of Modena, Modena, Italy
| | - S Fogli
- Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - U De Giorgi
- Unit of Medical Oncology, IRCCS-Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy
| | - R Danesi
- Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| |
Collapse
|
12
|
Cazzaniga ME, Vallini I, Montagna E, Amoroso D, Berardi R, Butera A, Cagossi K, Cavanna L, Ciccarese M, Cinieri S, Cretella E, De Conciliis E, Febbraro A, Ferraù F, Ferzi A, Baldelli A, Fontana A, Gambaro AR, Garrone O, Gebbia V, Generali D, Gianni L, Giovanardi F, Grassadonia A, Leonardi V, Marchetti P, Sarti S, Musolino A, Nicolini M, Putzu C, Riccardi F, Santini D, Saracchini S, Sarobba MG, Schintu MG, Scognamiglio G, Spadaro P, Taverniti C, Toniolo D, Tralongo P, Turletti A, Valenza R, Valerio MR, Vici P, Di Mauro P, Cogliati V, Capici S, Clivio L, Torri V. Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study. Breast Cancer Res Treat 2021; 190:415-424. [PMID: 34546500 PMCID: PMC8558172 DOI: 10.1007/s10549-021-06375-5] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2021] [Accepted: 08/26/2021] [Indexed: 11/30/2022]
Abstract
Purpose Triple-negative breast cancer (TNBC) represents a subtype of breast cancer which lacks the expression of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2): TNBC accounts for approximately 20% of newly diagnosed breast cancers and is associated with younger age at diagnosis, greater recurrence risk and shorter survival time. Therapeutic options are very scarce. Aim of the present analysis is to provide further insights into the clinical activity of metronomic chemotherapy (mCHT), in a real-life setting. Methods We used data included in the VICTOR-6 study for the present analysis. VICTOR-6 is an Italian multicentre retrospective cohort study, which collected data of metastatic breast cancer (MBC) patients who have received mCHT between 2011 and 2016. Amongst the 584 patients included in the study, 97 were triple negative. In 40.2% of the TNBC patients, mCHT was the first chemotherapy treatment, whereas 32.9% had received 2 or more lines of treatment for the metastatic disease. 45.4% out of 97 TNBC patients received a vinorelbine (VRL)-based regimen, which resulted in the most used type of mCHT, followed by cyclophosphamide (CTX)-based regimens (30.9%) and capecitabine (CAPE)-based combinations (22.7%). Results Overall response rate (ORR) and disease control rate (DCR) were 17.5% and 64.9%, respectively. Median progression free survival (PFS) and overall survival (OS) were 6.0 months (95% CI: 4.9–7.2) and 12.1 months (95% CI: 9.6–16.7). Median PFS was 6.9 months for CAPE-based regimens (95% CI: 5.0–18.4), 6.1 months (95% CI: 4.0–8.9) for CTX-based and 5.3 months (95% CI: 4.1–9.5) for VRL-based ones. Median OS was 18.2 months (95% CI: 9.1-NE) for CAPE-based regimens and 11.8 months for VRL- (95% CI: 9.3–16.7 and CTX-based ones (95%CI: 8.7–52.8). Tumour response, PFS and OS decreased proportionally in later lines. Conclusion This analysis represents the largest series of TNBC patients treated with mCHT in a real-life setting and provides further insights into the advantages of using this strategy even in this poor prognosis subpopulation.
Collapse
Affiliation(s)
- M E Cazzaniga
- Phase 1 Research Centre and Oncology Unit, Department of Medicine and Surgery, University of Milano-Bicocca, ASST Monza, Via Pergolesi 33, 20900, Monza, MB, Italy.
- Oncology Unit, ASST Monza, Monza, MB, Italy.
| | - I Vallini
- Medical Oncology, ASST Sette Laghi Ospedale Di Circolo E Fondazione Macchi, Varese, VA, Italy
| | - E Montagna
- Medical Senology Division, IEO, Milan, Italy
| | - D Amoroso
- Medical Oncology, Ospedale Versilia, ATNO, Lido Di Camaiore, LU, Italy
| | - R Berardi
- Medical Oncology, Università Politecnica Delle Marche, AOU Ospedali Riuniti, Ancona, Italy
| | - A Butera
- Medical Oncology, Ospedale San Giovanni Di Dio, Agrigento, Italy
| | - K Cagossi
- Medical Oncology, Ospedale Ramazzini, Carpi, Italy
| | - L Cavanna
- Medical Oncology, Azienda Ospedaliera Piacenza, Piacenza, Italy
| | - M Ciccarese
- Medical Oncology, Ospedale Vito Fazzi, Lecce, Italy
| | - S Cinieri
- Medical Oncology, ASL Brindisi, Brindisi, Italy
| | - E Cretella
- Medical Oncology, Ospedale Bolzano, Bolzano, Italy
| | | | - A Febbraro
- Medical Oncology, Ospedale S. Cuore di Gesù Fatebenefratelli, Benevento, Italy
| | - F Ferraù
- Medical Oncology, Osp Taormina, Taormina, Italy
| | - A Ferzi
- Medical Oncology, A.S.S.T. Ovest Milanese Legnano, Legnano, Italy
| | - A Baldelli
- Medical Oncology, Ospedale San Salvatore, Pesaro, Italy
| | - A Fontana
- Medical Oncology 2, Az. Ospedaliero-Universitaria Pisana, Pisa, Italy
| | - A R Gambaro
- Medical Oncology, ASST Fatebenefratelli Sacco, Milano, Italy
| | - O Garrone
- Breast Unit Medical Oncology, A.O. S. Croce e Carle, Cuneo, Italy
| | - V Gebbia
- Medical Oncology, Ospedale La Maddalena, Palermo, Italy
| | - D Generali
- Medical Oncology, Istituti Ospitalieri Cremona, Cremona, Italy
| | - L Gianni
- Medical Oncology, Azienda USL Romagna, U.O. di Oncologia Rimini, Cattolica, Italy
| | - F Giovanardi
- AUSL IRCCS Reggio Emilia Provincial Oncology Unit, Reggio Emilia, Italy
| | - A Grassadonia
- Medical Oncology, P.O. SS Annunziata -ASL2 Lanciano-Vasto, Chieti, Italy
| | - V Leonardi
- Medical Oncology, Ospedale Civico, Palermo, Italy
| | - P Marchetti
- Medical Oncology, A.O. Sant'Andrea, Roma, Italy
| | - S Sarti
- IRCCS Istituto Romagnolo per lo studio dei Tumori (IRST) "Dino Amadori", 47014, Meldola, Italy
| | - A Musolino
- Department of Medicine and Surgery, Medical Oncology and Breast Unit, University of Parma and University Hospital of Parma, Parma, Italy
| | - M Nicolini
- Medical Oncology, Azienda USL Romagna, U.O. di Oncologia Rimini, Cattolica, Italy
| | - C Putzu
- Medical Oncology, A. Ospedaliera-Universitaria, Sassari, Italy
| | - F Riccardi
- Medical Oncology, A. Ospedaliera Antonio Cardarelli, Napoli, Italy
| | - D Santini
- Medical Oncology, Università Campus Bio-Medico, Roma, Italy
| | - S Saracchini
- Medical Oncology, Az. Osp. Santa Maria degli Angeli, Pordenone, Italy
| | - M G Sarobba
- Medical Oncology, Ospedale San Francesco, Nuoro, Italy
| | - M G Schintu
- Medical Oncology, Osp Giovanni Paolo II, Olbia, Italy
| | | | - P Spadaro
- Medical Oncology, Casa di Cura Villa Salus-Messina, Messina, Italy
| | - C Taverniti
- Medical Oncology, A.O.U. Città della Salute e della Scienza, Osp. Molinette, Torino, Italy
| | - D Toniolo
- Medical Oncology, ASST Rhodense, Ospedale di Circolo Rho, Rho, Italy
| | - P Tralongo
- Medical Oncology, Osp. Umberto I, Siracusa, Italy
| | - A Turletti
- Medical Oncology, P.O. Martini, Torino, Italy
| | - R Valenza
- Medical Oncology, P.O. Vittorio Emanuele, Gela, Italy
| | - M R Valerio
- Department of Discipline Chirurgiche, Oncologiche e Stomatologiche (DICHIRONS), Medical Oncology, A.O.U. Policlinico Paolo Giaccone, Palermo, Italy
| | - P Vici
- Phase IV trials, IRCCS, INT Regina Elena, Rome, Italy
| | - P Di Mauro
- Oncology Unit, ASST Monza, Monza, MB, Italy
| | - V Cogliati
- Phase 1 Research Centre and Oncology Unit, Department of Medicine and Surgery, University of Milano-Bicocca, ASST Monza, Via Pergolesi 33, 20900, Monza, MB, Italy
| | - S Capici
- Phase 1 Research Centre and Oncology Unit, Department of Medicine and Surgery, University of Milano-Bicocca, ASST Monza, Via Pergolesi 33, 20900, Monza, MB, Italy
| | - L Clivio
- Oncology Department, IRCCS Mario Negri Institute, Milan, Italy
| | - V Torri
- Oncology Department, IRCCS Mario Negri Institute, Milan, Italy
| |
Collapse
|
13
|
Del Re M, Omarini C, Diodati L, Palleschi M, Meattini I, Crucitta S, Isca C, Fogli S, Bleve S, Lorenzini G, Fontana A, Livi L, Piacentini F, De Giorgi U, Danesi R. 239P Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.522] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
14
|
Affiliation(s)
- A. Colombi
- INFN - Sezione di Pavia, I-27100 Pavia, Italy
- Università di Pavia,Dipartimento di Fisica, I-27100 Pavia, Italy
| | | | - F. Barbaro
- INFN - Sezione di Padova, I-35131 Padova, Italy
| | - L. Canton
- INFN - Sezione di Padova, I-35131 Padova, Italy
| | - A. Fontana
- INFN - Sezione di Pavia, I-27100 Pavia, Italy
| |
Collapse
|
15
|
Pellan L, Dieye CAT, Durand N, Fontana A, Strub C, Schorr-Galindo S. Biocontrol Agents: Toolbox for the Screening of Weapons against Mycotoxigenic Fusarium. J Fungi (Basel) 2021; 7:446. [PMID: 34205071 PMCID: PMC8226957 DOI: 10.3390/jof7060446] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2021] [Revised: 05/31/2021] [Accepted: 05/31/2021] [Indexed: 12/22/2022] Open
Abstract
The aim of this study was to develop a set of experiments to screen and decipher the mechanisms of biocontrol agents (BCAs), isolated from commercial formulation, against two major mycotoxigenic fungi in cereals, Fusarium graminearum and Fusarium verticillioides. These two phytopathogens produce mycotoxins harmful to human and animal health and are responsible for the massive use of pesticides, for the protection of cereals. It is therefore essential to better understand the mechanisms of action of alternative control strategies such as the use of BCAs in order to optimize their applications. The early and late stages of interaction between BCAs and pathogens were investigated from germination of spores to the effects on perithecia (survival form of pathogen). The analysis of antagonist activities of BCAs revealed different strategies of biocontrol where chronological, process combination and specialization aspects of interactions are discussed. Streptomyces griseoviridis main strategy is based on antibiosis with the secretion of several compounds with anti-fungal and anti-germination activity, but also a mixture of hydrolytic enzymes to attack pathogens, which compensates for an important deficit in terms of spatial colonization capacity. It has good abilities in terms of nutritional competition. Trichoderma asperellum is capable of activating a very wide range of defenses and attacks combining the synthesis of various antifungal compounds (metabolite, enzymes, VOCs), with different targets (spores, mycelium, mycotoxins), and direct action by mycoparasitism and mycophagy. Concerning Pythium oligandrum, its efficiency is mainly due to its strong capacity to colonize the environment, with a direct action via microbial predation, stimulation of its reproduction at the contact of pathogens and the reduction of perithecia formation.
Collapse
Affiliation(s)
- Lucile Pellan
- Qualisud, Univ Montpellier, Avignon Université, CIRAD, Institut Agro, IRD, Université de La Réunion, 34095 Montpellier, France; (L.P.); (C.A.T.D.); (N.D.); (A.F.); (S.S.-G.)
| | - Cheikh Ahmeth Tidiane Dieye
- Qualisud, Univ Montpellier, Avignon Université, CIRAD, Institut Agro, IRD, Université de La Réunion, 34095 Montpellier, France; (L.P.); (C.A.T.D.); (N.D.); (A.F.); (S.S.-G.)
| | - Noël Durand
- Qualisud, Univ Montpellier, Avignon Université, CIRAD, Institut Agro, IRD, Université de La Réunion, 34095 Montpellier, France; (L.P.); (C.A.T.D.); (N.D.); (A.F.); (S.S.-G.)
- CIRAD, UMR Qualisud, 34398 Montpellier, France
| | - Angélique Fontana
- Qualisud, Univ Montpellier, Avignon Université, CIRAD, Institut Agro, IRD, Université de La Réunion, 34095 Montpellier, France; (L.P.); (C.A.T.D.); (N.D.); (A.F.); (S.S.-G.)
| | - Caroline Strub
- Qualisud, Univ Montpellier, Avignon Université, CIRAD, Institut Agro, IRD, Université de La Réunion, 34095 Montpellier, France; (L.P.); (C.A.T.D.); (N.D.); (A.F.); (S.S.-G.)
| | - Sabine Schorr-Galindo
- Qualisud, Univ Montpellier, Avignon Université, CIRAD, Institut Agro, IRD, Université de La Réunion, 34095 Montpellier, France; (L.P.); (C.A.T.D.); (N.D.); (A.F.); (S.S.-G.)
| |
Collapse
|
16
|
Campos-Avelar I, Colas de la Noue A, Durand N, Cazals G, Martinez V, Strub C, Fontana A, Schorr-Galindo S. Aspergillus flavus Growth Inhibition and Aflatoxin B 1 Decontamination by Streptomyces Isolates and Their Metabolites. Toxins (Basel) 2021; 13:toxins13050340. [PMID: 34066812 PMCID: PMC8151643 DOI: 10.3390/toxins13050340] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2021] [Revised: 04/28/2021] [Accepted: 05/03/2021] [Indexed: 12/02/2022] Open
Abstract
Aflatoxin B1 is a potent carcinogen produced by Aspergillus flavus, mainly during grain storage. As pre-harvest methods are insufficient to avoid mycotoxin presence during storage, diverse curative techniques are being investigated for the inhibition of fungal growth and aflatoxin detoxification. Streptomyces spp. represent an alternative as they are a promising source of detoxifying enzymes. Fifty-nine Streptomyces isolates and a Streptomyces griseoviridis strain from the commercial product Mycostop®, evaluated against Penicillium verrucosum and ochratoxin A during previous work, were screened for their ability to inhibit Aspergillus flavus growth and decrease the aflatoxin amount. The activities of bacterial cells and cell-free extracts (CFEs) from liquid cultures were also evaluated. Fifty-eight isolates were able to inhibit fungal growth during dual culture assays, with a maximal reduction going down to 13% of the control. Aflatoxin-specific production was decreased by all isolates to at least 54% of the control. CFEs were less effective in decreasing fungal growth (down to 40% and 55% for unheated and heated CFEs, respectively) and aflatoxin-specific production, with a few CFEs causing an overproduction of mycotoxins. Nearly all Streptomyces isolates were able to degrade AFB1 when growing in solid and liquid media. A total degradation of AFB1 was achieved by Mycostop® on solid medium, as well as an almost complete degradation by IX20 in liquid medium (6% of the control). CFE maximal degradation went down to 37% of the control for isolate IX09. The search for degradation by-products indicated the presence of a few unknown molecules. The evaluation of residual toxicity of the tested isolates by the SOS chromotest indicated a detoxification of at least 68% of AFB1’s genotoxicity.
Collapse
Affiliation(s)
- Ixchel Campos-Avelar
- UMR Qualisud, University of Montpellier, 34095 Montpellier, France; (N.D.); (V.M.); (C.S.); (A.F.); (S.S.-G.)
- Correspondence: (I.C.-A.); (A.C.d.l.N.)
| | - Alexandre Colas de la Noue
- UMR Qualisud, University of Montpellier, 34095 Montpellier, France; (N.D.); (V.M.); (C.S.); (A.F.); (S.S.-G.)
- Correspondence: (I.C.-A.); (A.C.d.l.N.)
| | - Noël Durand
- UMR Qualisud, University of Montpellier, 34095 Montpellier, France; (N.D.); (V.M.); (C.S.); (A.F.); (S.S.-G.)
- CIRAD, UMR Qualisud, 34398 Montpellier, France
| | - Guillaume Cazals
- IBMMUMR5247, University of Montpellier, CNRS, ENSCM, Place Eugène Bataillon, 34095 Montpellier, France;
| | - Véronique Martinez
- UMR Qualisud, University of Montpellier, 34095 Montpellier, France; (N.D.); (V.M.); (C.S.); (A.F.); (S.S.-G.)
| | - Caroline Strub
- UMR Qualisud, University of Montpellier, 34095 Montpellier, France; (N.D.); (V.M.); (C.S.); (A.F.); (S.S.-G.)
| | - Angélique Fontana
- UMR Qualisud, University of Montpellier, 34095 Montpellier, France; (N.D.); (V.M.); (C.S.); (A.F.); (S.S.-G.)
| | - Sabine Schorr-Galindo
- UMR Qualisud, University of Montpellier, 34095 Montpellier, France; (N.D.); (V.M.); (C.S.); (A.F.); (S.S.-G.)
| |
Collapse
|
17
|
Mamounas EP, Untch M, Mano MS, Huang CS, Geyer CE, von Minckwitz G, Wolmark N, Pivot X, Kuemmel S, DiGiovanna MP, Kaufman B, Kunz G, Conlin AK, Alcedo JC, Kuehn T, Wapnir I, Fontana A, Hackmann J, Polikoff J, Saghatchian M, Brufsky A, Yang Y, Zimovjanova M, Boulet T, Liu H, Tesarowski D, Lam LH, Song C, Smitt M, Loibl S. Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE. Ann Oncol 2021; 32:1005-1014. [PMID: 33932503 DOI: 10.1016/j.annonc.2021.04.011] [Citation(s) in RCA: 50] [Impact Index Per Article: 16.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2020] [Revised: 04/13/2021] [Accepted: 04/20/2021] [Indexed: 12/26/2022] Open
Abstract
BACKGROUND In the KATHERINE study (NCT01772472), patients with residual invasive early breast cancer (EBC) after neoadjuvant chemotherapy (NACT) plus human epidermal growth factor receptor 2 (HER2)-targeted therapy had a 50% reduction in risk of recurrence or death with adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab. Here, we present additional exploratory safety and efficacy analyses. PATIENTS AND METHODS KATHERINE enrolled HER2-positive EBC patients with residual invasive disease in the breast/axilla at surgery after NACT containing a taxane (± anthracycline, ± platinum) and trastuzumab (± pertuzumab). Patients were randomized to adjuvant T-DM1 (n = 743) or trastuzumab (n = 743) for 14 cycles. The primary endpoint was invasive disease-free survival (IDFS). RESULTS The incidence of peripheral neuropathy (PN) was similar regardless of neoadjuvant taxane type. Irrespective of treatment arm, baseline PN was associated with longer PN duration (median, 105-109 days longer) and lower resolution rate (∼65% versus ∼82%). Prior platinum therapy was associated with more grade 3-4 thrombocytopenia in the T-DM1 arm (13.5% versus 3.8%), but there was no grade ≥3 hemorrhage in these patients. Risk of recurrence or death was decreased with T-DM1 versus trastuzumab in patients who received anthracycline-based NACT [hazard ratio (HR) = 0.51; 95% confidence interval (CI): 0.38-0.67], non-anthracycline-based NACT (HR = 0.43; 95% CI: 0.22-0.82), presented with cT1, cN0 tumors (0 versus 6 IDFS events), or had particularly high-risk tumors (HRs ranged from 0.43 to 0.72). The central nervous system (CNS) was more often the site of first recurrence in the T-DM1 arm (5.9% versus 4.3%), but T-DM1 was not associated with a difference in overall risk of CNS recurrence. CONCLUSIONS T-DM1 provides clinical benefit across patient subgroups, including small tumors and particularly high-risk tumors and does not increase the overall risk of CNS recurrence. NACT type had a minimal impact on safety.
Collapse
Affiliation(s)
- E P Mamounas
- NSABP Foundation and; Department of Surgery, Orlando Health UF Health Cancer Center, Orlando, USA.
| | - M Untch
- AGO-B and Department of Gynecologic Oncology, HELIOS Klinikum Berlin Buch, Berlin, Germany
| | - M S Mano
- Department of Radiology and Oncology, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil
| | - C-S Huang
- Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
| | - C E Geyer
- NSABP Foundation and; NSABP Foundation and Department of Internal Medicine, Division of Hematology and Medical Oncology, Houston Methodist Cancer Center, Houston, USA
| | | | - N Wolmark
- NSABP Foundation and; NSABP Foundation and Department of Surgery, The University of Pittsburgh, Pittsburgh, USA
| | | | - S Kuemmel
- Breast Unit Kliniken Essen-Mitte, Essen, Germany; Klinik für Gynäkologie mit Brustzentrum Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - M P DiGiovanna
- Yale University School of Medicine, Yale Cancer Center and Smilow Cancer Hospital, New Haven, USA
| | - B Kaufman
- Oncology Division, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
| | - G Kunz
- GBG, Neu-Isenburg, Germany; St. Johannes Hospital Dortmund, Dortmund, Germany
| | - A K Conlin
- NSABP Foundation and; NSABP Foundation and Department of Medical Oncology, Providence Cancer Institute, Portland, USA
| | - J C Alcedo
- Department of Clinical Oncology, Centro Hemato Oncologico, Panama City, Panama
| | - T Kuehn
- AGO-B and Klinikum Esslingen, Esslingen, Germany
| | - I Wapnir
- NSABP Foundation and; NSABP Foundation and Stanford University School of Medicine, Stanford, USA
| | - A Fontana
- Division of Medical Oncology, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
| | - J Hackmann
- GBG, Neu-Isenburg, Germany; Marien-Hospital Witten, SEG, Witten, Germany
| | - J Polikoff
- NSABP Foundation and; NSABP Foundation and Department of Hematology/Oncology, Kaiser Permanente, San Diego, USA
| | - M Saghatchian
- Breast Cancer Department, Institut Gustave Roussy, Villejuif, France
| | - A Brufsky
- NSABP Foundation and; NSABP Foundation and Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, USA
| | - Y Yang
- Division of Hematology-Oncolog, Taichung Veterans General Hospital and School of Medicine, China Medical University, Taichung City, Taiwan
| | - M Zimovjanova
- Department of Oncology, Charles University and General University Hospital, Prague, Czech Republic
| | - T Boulet
- Department of Biostatistics, F. Hoffmann-La Roche, Basel, Switzerland
| | - H Liu
- Product Development Safety, Genentech, Inc., South San Francisco, USA
| | - D Tesarowski
- Product Development Oncology, Genentech, Inc., South San Francisco, USA
| | - L H Lam
- Product Development Oncology, Genentech, Inc., South San Francisco, USA
| | - C Song
- Product Development Oncology, Genentech, Inc., South San Francisco, USA
| | - M Smitt
- Product Development Oncology, Genentech, Inc., South San Francisco, USA; Seattle Genetics, South San Francisco, USA
| | - S Loibl
- GBG, Neu-Isenburg, Germany; Center for Haematology and Oncology Bethanien, Frankfurt, Germany
| |
Collapse
|
18
|
Meattini I, Rocco N, Bernini M, Bonzano E, De Rose F, De Santis M, Franco P, Meduri B, Parisi S, Pasinetti N, Prisco A, Fontana A, Becherini C, Livi L. Breast reconstruction and radiation therapy: consensus statements of the Italian association of radiotherapy and clinical oncology (AIRO) breast cancer group. Breast 2021. [DOI: 10.1016/s0960-9776(21)00160-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
19
|
Al Riachy R, Strub C, Durand N, Guibert B, Guichard H, Constancias F, Chochois V, Lopez-Lauri F, Fontana A, Schorr-Galindo S. Microbiome Status of Cider-Apples, from Orchard to Processing, with a Special Focus on Penicillium expansum Occurrence and Patulin Contamination. J Fungi (Basel) 2021; 7:jof7040244. [PMID: 33805022 PMCID: PMC8063962 DOI: 10.3390/jof7040244] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2021] [Revised: 03/15/2021] [Accepted: 03/19/2021] [Indexed: 11/22/2022] Open
Abstract
Patulin is a secondary metabolite produced primarily by the fungus Penicillium expansum, responsible for the blue mold disease on apples. It is found in apple products including apple cider when apple juice is added after fermentation. In the present study, two hundred and twenty-five cider-apples of the variety “Bedan”, cultivated in Brittany in France, were sampled from the orchard during harvesting until the storage step, right before processing. The patulin analysis on these samples reported a low contamination at the orchard and a significantly higher-level of contamination in the cider-apples starting from the transporting bin. The percentage of positive samples increased from 6% to 47% after 12 h in the harvesting bin before transporting and reached 95% after 24 h of transporting, decreasing then to 69% at the end of the storage. Penicillium expansum was quantified on the surface of apples using real-time PCR and was observed to be mostly consistent between the harvest and post-harvest steps. It was detected on average, on the surface of 85% of all sampled apples with a mean value around 2.35 × 106Penicillium expansum DNA/g of apple. Moreover, the changes in the fungal and bacterial epiphytic microbiota in the different steps were studied using a metabarcoding approach. The alpha and beta diversity analysis revealed the presence of unique and more diverse bacterial and fungal communities on the surface of apples picked from the orchard compared to the rest of the sampling steps. Potential indigenous biological control agents were identified on the surface of sampled apples. Future perspective includes developing actions of prevention and control of the contamination by Penicillium expansum during the harvest and along the various critical post-harvest stages before transformation in a sustainable development concern.
Collapse
Affiliation(s)
- Reem Al Riachy
- Qualisud, Univ Montpellier, CIRAD, Univ d’Avignon, Institut Agro, IRD, Univ de La Réunion, F-34398 Montpellier, France; (N.D.); (B.G.); (F.C.); (V.C.); (F.L.-L.); (A.F.); (S.S.-G.)
- Correspondence: (R.A.R.); (C.S.)
| | - Caroline Strub
- Qualisud, Univ Montpellier, CIRAD, Univ d’Avignon, Institut Agro, IRD, Univ de La Réunion, F-34398 Montpellier, France; (N.D.); (B.G.); (F.C.); (V.C.); (F.L.-L.); (A.F.); (S.S.-G.)
- Correspondence: (R.A.R.); (C.S.)
| | - Noël Durand
- Qualisud, Univ Montpellier, CIRAD, Univ d’Avignon, Institut Agro, IRD, Univ de La Réunion, F-34398 Montpellier, France; (N.D.); (B.G.); (F.C.); (V.C.); (F.L.-L.); (A.F.); (S.S.-G.)
- CIRAD, UMR Qualisud, F-34398 Montpellier, France
| | - Benjamin Guibert
- Qualisud, Univ Montpellier, CIRAD, Univ d’Avignon, Institut Agro, IRD, Univ de La Réunion, F-34398 Montpellier, France; (N.D.); (B.G.); (F.C.); (V.C.); (F.L.-L.); (A.F.); (S.S.-G.)
- CIRAD, UMR Qualisud, F-34398 Montpellier, France
| | - Hugues Guichard
- French Institute for Cider Production (IFPC), Domaine de la Motte, F-35653 Le Rheu, France;
| | - Florentin Constancias
- Qualisud, Univ Montpellier, CIRAD, Univ d’Avignon, Institut Agro, IRD, Univ de La Réunion, F-34398 Montpellier, France; (N.D.); (B.G.); (F.C.); (V.C.); (F.L.-L.); (A.F.); (S.S.-G.)
- CIRAD, UMR Qualisud, F-34398 Montpellier, France
| | - Vincent Chochois
- Qualisud, Univ Montpellier, CIRAD, Univ d’Avignon, Institut Agro, IRD, Univ de La Réunion, F-34398 Montpellier, France; (N.D.); (B.G.); (F.C.); (V.C.); (F.L.-L.); (A.F.); (S.S.-G.)
- CIRAD, UMR Qualisud, F-34398 Montpellier, France
| | - Félicie Lopez-Lauri
- Qualisud, Univ Montpellier, CIRAD, Univ d’Avignon, Institut Agro, IRD, Univ de La Réunion, F-34398 Montpellier, France; (N.D.); (B.G.); (F.C.); (V.C.); (F.L.-L.); (A.F.); (S.S.-G.)
| | - Angélique Fontana
- Qualisud, Univ Montpellier, CIRAD, Univ d’Avignon, Institut Agro, IRD, Univ de La Réunion, F-34398 Montpellier, France; (N.D.); (B.G.); (F.C.); (V.C.); (F.L.-L.); (A.F.); (S.S.-G.)
| | - Sabine Schorr-Galindo
- Qualisud, Univ Montpellier, CIRAD, Univ d’Avignon, Institut Agro, IRD, Univ de La Réunion, F-34398 Montpellier, France; (N.D.); (B.G.); (F.C.); (V.C.); (F.L.-L.); (A.F.); (S.S.-G.)
| |
Collapse
|
20
|
Gallorini M, Di Carlo R, Pilato S, Ricci A, Schweikl H, Cataldi A, Fontana A, Zara S. Liposomes embedded with differentiating factors as a new strategy for enhancing DPSC osteogenic commitment. Eur Cell Mater 2021; 41:108-120. [PMID: 33501637 DOI: 10.22203/ecm.v041a08] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
Human dental pulp stem cell (DPSC) differentiation toward the osteoblastic phenotype is enhanced when culture media are supplemented with differentiating factors, i.e. ascorbic acid, β-glycerophosphate and dexamethasone. Liposomes, spherical vesicles formed by a phospholipid bilayer, are frequently used as carriers for drugs, growth factors and hydrophobic molecules. The aim of this work was to speed up DPSC commitment to the osteogenic lineage by embedding differentiating factors within liposomes. Firstly, liposomes were prepared by rehydrating a phospholipidic thin film and characterised in terms of dimensions. Secondly, liposome-exposed DPSCs were characterised by their immunophenotypic profile. Levels of CD90 were significantly decreased in the presence of liposomes filled with ascorbic acid, β-glycerophosphate and dexamethasone (Lipo-Mix) with respect to normal differentiation medium (DM), while CD73 and CD29 expression were enhanced, suggesting osteogenic commitment. Additionally, an appreciable extracellular matrix deposition is detected. Thirdly, the Lipo-Mix formulation better increases alkaline phosphatase activity and levels of Collagen I secretion with respect to DM. In parallel, the new liposome formulation is capable of decreasing the release of H2O2 and of triggering a precocious antioxidant cell response, redressing the redox balance required upon mesenchymal stem cell commitment to osteogenesis. It can be therefore hypothesised that Lipo-Mix could represent a suitable tool for clinical regenerative purposes in the field of tissue engineering by speeding up DPSC osteogenic commitment, mineralised matrix deposition and remodelling.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - S Zara
- University "G. d'Annunzio" Chieti-Pescara, 66100, Chieti,
| |
Collapse
|
21
|
d'Ippolito G, Squadrito G, Tucci M, Esercizio N, Sardo A, Vastano M, Lanzilli M, Fontana A, Cristiani P. Electrostimulation of hyperthermophile Thermotoga neapolitana cultures. Bioresour Technol 2021; 319:124078. [PMID: 33254443 DOI: 10.1016/j.biortech.2020.124078] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/01/2020] [Revised: 08/30/2020] [Accepted: 08/31/2020] [Indexed: 06/12/2023]
Abstract
Hyperthermophile bioelectrochemical systems are seldom investigated although their superior control of microbial consortium and thermodynamic advantages. Hyperthermophilic Thermotogales, for instance, are able to produce hydrogen and lactic acid from wastes better than mesophilic bacteria. Here, the electrostimulation of Thermotoga neapolitana in single-chamber electrochemical bioreactors is studied. The glucose fermentation under CO2 pressure, as model metabolism, was tested at 80 °C. Results show that a dynamic polarization (±0.8 to ±1.2 V) drives glucose fermentation and biofilm stasis on electrodes. Under this condition, production of lactic acid (33 vs 12 mM) and yields of acetate and hydrogen (with lactic/acetic acid ratio of 1.18) were higher than those achieved with static polarization or open-circuit. Dynamic polarization is possibly exploitable to stimulate T. neapolitana in a hyperthermophile electrochemical system for various applications including control of power-to-gas processes or production of value-added products (hydrogen and lactic acid) from sugary wastes.
Collapse
Affiliation(s)
- G d'Ippolito
- Institute of Biomolecular Chemsitry (ICB), National Research Council (CNR), Pozzuoli, Na, Italy
| | - G Squadrito
- Istitute of Advanced Tecnologies for Energy (ITAE), National Research Council (CNR), Messina, Italy
| | - M Tucci
- Water Research Institute (IRSA), National Research Council (CNR), Via Salaria km29, 300 00015 Monterotondo, Rome, Italy; e-Bio Center, Department of Environmental Science and Policy, Università degli Studi di Milano, via Celoria 2, 20133 Milan, Italy
| | - N Esercizio
- Institute of Biomolecular Chemsitry (ICB), National Research Council (CNR), Pozzuoli, Na, Italy
| | - A Sardo
- Institute of Biomolecular Chemsitry (ICB), National Research Council (CNR), Pozzuoli, Na, Italy
| | - M Vastano
- Institute of Biomolecular Chemsitry (ICB), National Research Council (CNR), Pozzuoli, Na, Italy
| | - M Lanzilli
- Institute of Biomolecular Chemsitry (ICB), National Research Council (CNR), Pozzuoli, Na, Italy
| | - A Fontana
- Institute of Biomolecular Chemsitry (ICB), National Research Council (CNR), Pozzuoli, Na, Italy
| | - P Cristiani
- Ricerca sul Sistema Energetico - RSE S.p.A., via Rubattino, 54, 20134 Milano, Italy.
| |
Collapse
|
22
|
Marino S, Marino L, Greco F, Venti V, Fontana A, Timpanaro T, Taibi R, Pustorino E, Barbagallo M, Pavone P. Bickerstaff's brainstem encephalitis in childhood: a literature overview. Eur Rev Med Pharmacol Sci 2020; 24:12802-12807. [PMID: 33378029 DOI: 10.26355/eurrev_202012_24181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
OBJECTIVE This is a review on clinical presentation, diagnosis, and treatment of reported cases of Bickerstaff brain encephalitis. MATERIALS AND METHODS Cases of pediatric Bickerstaff's brainstem encephalitis collected from PubMed, Cochrane Library and Scopus Web of Science databases were reviewed. The inclusion criteria of the cases were based on age ≤ 18 years and the clinical characteristics of the disorder. RESULTS Twenty-seven articles on Bickerstaff's brainstem encephalitis, including 236 children from a total of 42 from January 1990 to January 2020, were selected. The phenotype of the pediatric cases confirmed those described in the previously published articles. Almost half of the cases demonstrated the positivity of anti-GQ1b antibody titers, but the antibodies' presence was not linked to longer healing time. However, it was found that individuals with neuroimaging changes needed a longer time to recovery. Overall, patients treated with any type of immunotherapy (intravenous immunoglobulins, steroid or plasmapheresis) demonstrated faster resolution of symptoms than supportive care. CONCLUSIONS Bickerstaff's brainstem encephalitis is an uncommon disorder, the short-term and long-term prognoses depend on the clinical presentation of the disorder, co-morbidity, instrumental investigations, and precocity of treatment.
Collapse
Affiliation(s)
- S Marino
- Pediatric and Pediatric Emergency Department, University Hospital "Policlinico-San Marco, Catania, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Yapo AE, Strub C, Durand N, Ahoua ARC, Schorr-Galindo S, Bonfoh B, Fontana A, Koussémon M. Mass spectrometry-based detection and risk assessment of mycotoxin contamination of ‘kankankan’ used for roasted meat consumption in Abidjan, Côte d’Ivoire. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2020; 37:1564-1578. [DOI: 10.1080/19440049.2020.1784468] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Armel Elysée Yapo
- Department of Food Science and Technology, Université Nangui Abrogoua, Abidjan, Côte d’Ivoire
- Department Research and Development, Centre Suisse De Recherches Scientifiques En Côte d’Ivoire (CSRS), Abidjan, Côte d’Ivoire
| | - Caroline Strub
- QualiSud, Univ Montpellier, CIRAD, Montpellier SupAgro, Univ d’Avignon, Univ De La Réunion, Montpellier, France
| | - Noël Durand
- QualiSud, Univ Montpellier, CIRAD, Montpellier SupAgro, Univ d’Avignon, Univ De La Réunion, Montpellier, France
- CIRAD, UMR Qualisud, Montpellier, France
| | - Angora Rémi Constant Ahoua
- Department Research and Development, Centre Suisse De Recherches Scientifiques En Côte d’Ivoire (CSRS), Abidjan, Côte d’Ivoire
| | - Sabine Schorr-Galindo
- QualiSud, Univ Montpellier, CIRAD, Montpellier SupAgro, Univ d’Avignon, Univ De La Réunion, Montpellier, France
| | - Bassirou Bonfoh
- Department Research and Development, Centre Suisse De Recherches Scientifiques En Côte d’Ivoire (CSRS), Abidjan, Côte d’Ivoire
| | - Angélique Fontana
- QualiSud, Univ Montpellier, CIRAD, Montpellier SupAgro, Univ d’Avignon, Univ De La Réunion, Montpellier, France
| | - Marina Koussémon
- Department of Food Science and Technology, Université Nangui Abrogoua, Abidjan, Côte d’Ivoire
| |
Collapse
|
24
|
Romano C, Cho SY, Marino S, Raucci U, Fiumara A, Falsaperla R, Massimino CR, Taibi R, Greco F, Venti V, Sullo F, Fontana A, Rizzo R, Pustorino E, Jin DK, Pavone P. Primary headache in childhood associated with psychiatric disturbances: an update. Eur Rev Med Pharmacol Sci 2020; 24:6893-6898. [PMID: 32633382 DOI: 10.26355/eurrev_202006_21680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE Primary headache disorders in children are one of the most prominent topics in the pediatric neurology literature. However, there are many unsolved aspects, including the conditions associated with migraine. The present study aims to report on the frequency of behavioral comorbidities in the setting of primary headache in childhood. PATIENTS AND METHODS In this study, we enlisted 475 children (290 males and 185 females; ratio 1.6:1), aged 4 to 14 years, who were affected by primary headache. In direct interviews, children and parents gave information on the association of their headache with, attention-deficit/hyperactivity disorder, learning disabilities, tics, anxiety, depression, and obsessive-compulsive disorder. Other 475 children with no history of headache or recognized neurological conditions were matched for age, sex, race, and socioeconomic status and were used as controls. RESULTS A significant association of primary headache was found with anxiety and depression (p-value <0.001); overall, behavioral disorders were more common in children who experienced headache than in controls (p-value <0.001). CONCLUSIONS Primary headache in children is not associated with most of the common behavioral conditions. On the contrary, there was a significant association with anxiety and depression, as reported in adults.
Collapse
Affiliation(s)
- C Romano
- Department Clinical and Experimental Medicine, Child and Adolescent Neuropsychiatry, University of Catania, Catania, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Boiardi L, Muratore F, Restuccia G, Cavazza A, Catanoso MG, Macchioni P, Spaggiari L, Cimino L, Aldigeri R, Pipitone N, Fontana A, Csaali M, Croci S, Girolimetto N, Salvarani C. THU0314 RELAPSES AND LONG-TERM REMISSION IN LARGE VESSEL GIANT CELL ARTERITIS IN NORTHERN ITALY: CHARACTERISTICS AND PREDICTORS IN A LONG-TERM FOLLOW-UP STUDY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.4729] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Previous studies evaluated clinical relapses and long-term remission mainly in patients with biopsy-proven GCA and/or patients satisfying the ACR 1990 criteria for GCA classification. Also, radiological involvement was unfrequently used to define relapses and monitor disease activity in patients with LV-GCAObjectives:To evaluate characteristics and predictors of relapses and long-term remission in an Italian cohort of patients with large-vessel (LV) giant cell arteritis (GCA).Methods:We evaluated 87 consecutive patients with LV-GCA followed up at the Rheumatology Unit of Reggio Emilia Hospital (Italy) for at least 2 years. Patients with relapses and long-term remission were compared to those without. A comparison group of 34 patients with biopsy proven GCA without LV vasculitis (LVV) at diagnosis was considered for comparison.Results:37 patients (42.5%) experienced one or more relapses. Nineteen (37.2%) of the 51 relapses were experienced during the first year after diagnosis. The majority of relapses occurred with doses of prednisone (PDN) ≤ 10 mg/day (74.5%). Polymyalgia rheumatica (PMR) (41.2%) and worsening at imaging of LVV (39.2%) were the most frequently observed relapsing manifestations. The total cumulative prednisone dose was significantly higher (p = 0.0001) and the total duration of PDN treatment longer (p = 0.0001) in relapsing patients compared to those without relapses. Relapsing patients had at diagnosis more frequently fever ≥ 38°C (p = 0.03) and visual manifestations (p = 0.03), and less frequently long-term remission (p = 0.003). In the multivariate model fever ≥ 38 °C (HR 3.22, 95%CI:1.43-7.27),duration of PDN treatment (HR 1.01, 95%CI: 1.00-1.02) and total cumulative PDN dose (HR 1.20, 95%CI: 1.09-1.33) were significantly associated with an increased risk of relapses, while aortic arch involvement at imaging at diagnosis (HR 0.22, 95%CI: 0.09-0.55) and long-term remission (HR 0.30, 95%CI: 0.12-0.75) with a reduced risk. 37 patients (42.5%) experienced long-term remission. PMR and disease relapses were less frequently observed (p = 0.003 for both), and the total cumulative prednisone dose was lower (p = 0.005) in patients with long-term remission compared to those without. In the multivariate model the presence of relapses (HR 0.33, 95%CI: 0.14-0.78) and the total cumulative PDN dose (HR 0.89, 95%CI: 0.83-0.96) were significantly negatively associated with long-term remission.Conclusion:In our cohort of patients with LV GCA we identified predictors of a relapsing course and long-term remission, which were observed in around half of the patients.Disclosure of Interests:luigi boiardi: None declared, Francesco Muratore: None declared, Giovanna Restuccia: None declared, Alberto Cavazza: None declared, Maria Grazia Catanoso: None declared, Pierluigi Macchioni: None declared, Lucia Spaggiari: None declared, Luca Cimino: None declared, Raffaella Aldigeri: None declared, Nicolò Pipitone: None declared, Antonio Fontana: None declared, Massimiliano Csaali: None declared, Stefania Croci: None declared, Nicolò Girolimetto: None declared, Carlo Salvarani Grant/research support from: consulting and investigator fees from Abbvie, Pfizer, MSD, Roche, Celgene, Novartis, Consultant of: consulting and investigator fees from Abbvie, Pfizer, MSD, Roche, Celgene, Novartis
Collapse
|
26
|
Milone M, Degiuli M, Allaix ME, Ammirati CA, Anania G, Barberis A, Belli A, Bianchi PP, Bianco F, Bombardini C, Burati M, Cavaliere D, Coco C, Coratti A, De Luca R, De Manzoni G, De Nardi P, De Rosa M, Delrio P, Di Cataldo A, Di Leo A, Donini A, Elmore U, Fontana A, Gallo G, Gentilli S, Giannessi S, Giuliani G, Graziosi L, Guerrieri M, Li Destri G, Longhin R, Manigrasso M, Mineccia M, Monni M, Morino M, Ortenzi M, Pecchini F, Pedrazzani C, Piccoli M, Pollesel S, Pucciarelli S, Reddavid R, Rega D, Rigamonti M, Rizzo G, Robustelli V, Rondelli F, Rosati R, Roviello F, Santarelli M, Saraceno F, Scabini S, Sica GS, Sileri P, Simone M, Siragusa L, Sofia S, Solaini L, Tribuzi A, Trompetto M, Turri G, Urso EDL, Vertaldi S, Vignali A, Zuin M, Zuolo M, D'Ugo D, De Palma GD. Mid-transverse colon cancer and extended versus transverse colectomy: Results of the Italian society of surgical oncology colorectal cancer network (SICO CCN) multicenter collaborative study. Eur J Surg Oncol 2020; 46:1683-1688. [PMID: 32220542 DOI: 10.1016/j.ejso.2020.01.006] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2019] [Accepted: 01/03/2020] [Indexed: 02/06/2023] Open
Abstract
INTRODUCTION Transverse colon cancer (TCC) is poorly studied, and TCC cases are often excluded from large prospective randomized trials because of their complexity and their potentially high complication rate. The best surgical approach for TCC has yet to be established. The aim of this large retrospective multicenter Italian series is to investigate the advantages and disadvantages of both hemicolectomy and transverse colectomy in order to identify the best surgical approach. MATERIALS AND METHODS This was a retrospective cohort study of patients with mid-transverse colon cancer treated with a segmental colon resection or an extended hemicolectomy (right or left) between 2006 and 2016 in 28 high-volume (more than 70 procedures/year) Italian referral centers for colorectal surgery. RESULTS The study included 1529 patients, 388 of whom underwent a segmental resection while 1141 underwent an extended resection. A higher number of complications has been reported in the segmental group than in the extended group (30.1% versus 23.6%; p 0.010). In 42 cases the main complication was the anastomotic leak (4.4% versus 2.2%; p 0.020). Recovery outcomes also showed statistical differences: time to first flatus (p 0.014), time to first mobilization (p 0.040), and overall hospital stay (p < 0.001) were significantly shorter in the extended group. Even if overall survival were similar between the groups (95.1% versus 97%; p 0.384), 3-year disease-free survival worsened after segmental resection (78.1% versus 86.2%; p 0.001). CONCLUSIONS According to our results, an extended right colon resection for TCC seems to be surgically safer and more oncologically valid.
Collapse
Affiliation(s)
- M Milone
- Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy.
| | - M Degiuli
- Department of Oncology, Surgical Oncology and Digestive Surgery Unit, San Luigi University Hospital, Orbassano, Turin, Italy
| | - M E Allaix
- Department of Surgical Sciences, University of Turin, Turin, Italy
| | - C A Ammirati
- Oncologic Surgical Unit, Hospital Policlinic San Martino, Genova, Italy
| | - G Anania
- Department of Morphology, Experimental Medicine and Surgery, Section of General and Thoracic Surgery, University of Ferrara, Italy
| | - A Barberis
- Unit of General and Hepatobiliopancreatic Surgery, Galliera Hospital, Genova, Italy
| | - A Belli
- Division of Surgical Oncology, Department of Abdominal Oncology, IRCCS Fondazione "G. Pascale", Naples, Italy
| | - P P Bianchi
- Department of General and Minimally Invasive Surgery, Misericordia Hospital, Grosseto, Italy
| | - F Bianco
- Division of Surgical Oncology, Department of Abdominal Oncology, IRCCS Fondazione "G. Pascale", Naples, Italy
| | - C Bombardini
- Department of Morphology, Experimental Medicine and Surgery, Section of General and Thoracic Surgery, University of Ferrara, Italy
| | - M Burati
- Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy
| | - D Cavaliere
- General and Oncologic Surgery, Morgagni-Pierantoni Hospital, Forlì, Italy
| | - C Coco
- Department of General Surgery, Sacred Heart Catholic University, Rome, Italy
| | - A Coratti
- Division of Oncological and Robotic General Surgery, Careggi University Hospital, Florence, Italy
| | - R De Luca
- Department of Surgical Oncology, National Cancer Research Center, Giovanni Paolo II Tumor Institute, Bari, Italy
| | - G De Manzoni
- Department of Surgery, General and Upper GI, Surgery Division, University of Verona, Verona, Italy
| | - P De Nardi
- Division of Gastrointestinal Surgery, San Raffaele Scientific Institut, Milan, Italy
| | - M De Rosa
- Department of General Surgery, San Giovanni Battista Hospital, Foligno, Italy
| | - P Delrio
- Colorectal Abdominal Surgery Division, IRCCS Fondazione "G. Pascale", Naples, Italy
| | - A Di Cataldo
- Department of General Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy
| | - A Di Leo
- Department of Surgery, General and Upper GI, Surgery Division, University of Verona, Verona, Italy
| | - A Donini
- Department of General and Emergency Surgery, University of Perugia, Perugia, Italy
| | - U Elmore
- Division of Gastrointestinal Surgery, San Raffaele Scientific Institut, Milan, Italy
| | - A Fontana
- Department of HPB and Digestive Surgery, Ospedale Mauriziano Umberto I, Turin, Italy
| | - G Gallo
- Department of Colorectal Surgery, Santa Rita Clinic, Vercelli, Italy
| | - S Gentilli
- Department of General Surgery, Maggiore della Carità Hospital, Novara, Italy
| | - S Giannessi
- Operative Unit of General Surgery, San Jacopo Hospital, Pistoia, Italy
| | - G Giuliani
- Department of General and Minimally Invasive Surgery, Misericordia Hospital, Grosseto, Italy
| | - L Graziosi
- Department of General and Emergency Surgery, University of Perugia, Perugia, Italy
| | - M Guerrieri
- Department of General Surgery, Università Politecnica delle Marche, Ancona, Italy
| | - G Li Destri
- Department of General Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy
| | - R Longhin
- Unit of General and Hepatobiliopancreatic Surgery, Galliera Hospital, Genova, Italy
| | - M Manigrasso
- Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy
| | - M Mineccia
- Department of HPB and Digestive Surgery, Ospedale Mauriziano Umberto I, Turin, Italy
| | - M Monni
- Department of General Surgery, Maggiore della Carità Hospital, Novara, Italy
| | - M Morino
- Department of Surgical Sciences, University of Turin, Turin, Italy
| | - M Ortenzi
- Department of General Surgery, Università Politecnica delle Marche, Ancona, Italy
| | - F Pecchini
- Department of General and Emergency Surgery, Azienda Ospedaliera Universitaria Modena, Modena, Italy
| | - C Pedrazzani
- Division of General and Hepatobiliary Surgery, Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, Unit of Colorectal Surgery, University of Verona, Verona, Italy
| | - M Piccoli
- Department of General and Emergency Surgery, Azienda Ospedaliera Universitaria Modena, Modena, Italy
| | - S Pollesel
- Department of General Surgery and Surgical Oncology, University of Siena, Italy
| | - S Pucciarelli
- Department of Surgical, Oncological and Gastroenterological Sciences, University of Padova, Padova, Italy
| | - R Reddavid
- Department of Oncology, Surgical Oncology and Digestive Surgery Unit, San Luigi University Hospital, Orbassano, Turin, Italy
| | - D Rega
- Colorectal Abdominal Surgery Division, IRCCS Fondazione "G. Pascale", Naples, Italy
| | - M Rigamonti
- Operative Unit of General Surgery, Valli del Noce Hospital, Cles, Trento, Italy
| | - G Rizzo
- Department of General Surgery, Sacred Heart Catholic University, Rome, Italy
| | - V Robustelli
- Operative Unit of General Surgery, San Jacopo Hospital, Pistoia, Italy
| | - F Rondelli
- Department of General Surgery, San Giovanni Battista Hospital, Foligno, Italy
| | - R Rosati
- Division of Gastrointestinal Surgery, San Raffaele Scientific Institut, Milan, Italy
| | - F Roviello
- Department of General Surgery and Surgical Oncology, University of Siena, Italy
| | - M Santarelli
- Division of General and Emergency Surgery, Molinette Hospital, Turin, Italy
| | - F Saraceno
- Department of General Surgery, University of Rome Tor Vergata, Rome, Italy
| | - S Scabini
- Oncologic Surgical Unit, Hospital Policlinic San Martino, Genova, Italy
| | - G S Sica
- Department of Minimally Invasive and GI Surgery, Policlinico Tor Vergata, Rome, Italy
| | - P Sileri
- Department of General Surgery, University of Rome Tor Vergata, Rome, Italy
| | - M Simone
- Department of Surgical Oncology, National Cancer Research Center, Giovanni Paolo II Tumor Institute, Bari, Italy
| | - L Siragusa
- Department of Minimally Invasive and GI Surgery, Policlinico Tor Vergata, Rome, Italy
| | - S Sofia
- Department of Oncology, Surgical Oncology and Digestive Surgery Unit, San Luigi University Hospital, Orbassano, Turin, Italy
| | - L Solaini
- General and Oncologic Surgery, Morgagni-Pierantoni Hospital, Forlì, Italy
| | - A Tribuzi
- Division of Oncological and Robotic General Surgery, Careggi University Hospital, Florence, Italy
| | - M Trompetto
- Department of Colorectal Surgery, Santa Rita Clinic, Vercelli, Italy
| | - G Turri
- Division of General and Hepatobiliary Surgery, Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, Unit of Colorectal Surgery, University of Verona, Verona, Italy
| | - E D L Urso
- Department of Surgical, Oncological and Gastroenterological Sciences, University of Padova, Padova, Italy
| | - S Vertaldi
- Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy
| | - A Vignali
- Division of Gastrointestinal Surgery, San Raffaele Scientific Institut, Milan, Italy
| | - M Zuin
- Department of Surgical, Oncological and Gastroenterological Sciences, University of Padova, Padova, Italy
| | - M Zuolo
- Operative Unit of General Surgery, Valli del Noce Hospital, Cles, Trento, Italy
| | - D D'Ugo
- Department of Surgery, Università Cattolica del Sacro Cuore, Rome, Italy
| | - G D De Palma
- Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy
| |
Collapse
|
27
|
Houissa H, Lasram S, Sulyok M, Šarkanj B, Fontana A, Strub C, Krska R, Schorr-Galindo S, Ghorbel A. Multimycotoxin LC-MS/MS analysis in pearl millet (Pennisetum glaucum) from Tunisia. Food Control 2019. [DOI: 10.1016/j.foodcont.2019.106738] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
28
|
Strub C, Dieye CAT, Nguyen PA, Constancias F, Durand N, Guendouz S, Pratlong M, Fontana A, Schorr-Galindo S. Transcriptomes of the interaction between Fusarium verticillioides and a Streptomyces strain reveal the fungal defense strategy under the pressure of a potential biocontrol agent. Fungal Biol 2019; 125:78-88. [PMID: 33518208 DOI: 10.1016/j.funbio.2019.11.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2019] [Revised: 10/31/2019] [Accepted: 11/12/2019] [Indexed: 12/17/2022]
Abstract
The actinobacteria Streptomyces sp. AV05 appears to be a potential biocontrol agent (BCA) against mycotoxigenic fungi. It was found to significantly inhibit F. verticillioides growth and mycotoxin production during their co-cultivation. F. verticillioides growth was durably affected while the decrease of the toxin production levels was reversible, suggesting different BCA actions. The study of both transcriptomes brought useful information on the microbial interaction. RNA-seq data indicated that the dual interaction modified genetic expression of both microorganisms as 18.5 % of the genes were differentially expressed for the fungus against 3.8 % for the actinobacteria. Fungal differentially expressed genes (DEGs) were equally up and down regulated while bacterial ones were mainly upregulated. We especially focused the analysis of DEGs on fungal defense reaction to bacterial attack. For example, if this potential BCA implements a strategy of antibiosis with the over expression of 'siderophore-interacting protein' linked to the production of bacteriocins, the fungus in a state of stress is able to adapt its metabolism by up-regulation of amidase. It could correspond to the induction of resistance gene clusters and suggest a detoxification process. Moreover fumonisins-related pathway appears underexpressed in the presence of Streptomyces that explain the reduction of fumonisin accumulation observed.
Collapse
Affiliation(s)
- C Strub
- Qualisud, Univ Montpellier, CIRAD, Montpellier SupAgro, Univ d'Avignon, Univ de La Réunion, Montpellier, France
| | - C A T Dieye
- Qualisud, Univ Montpellier, CIRAD, Montpellier SupAgro, Univ d'Avignon, Univ de La Réunion, Montpellier, France
| | - P A Nguyen
- Qualisud, Univ Montpellier, CIRAD, Montpellier SupAgro, Univ d'Avignon, Univ de La Réunion, Montpellier, France
| | - F Constancias
- Qualisud, Univ Montpellier, CIRAD, Montpellier SupAgro, Univ d'Avignon, Univ de La Réunion, Montpellier, France; CIRAD, UMR Qualisud, F-34398, Montpellier, France
| | - N Durand
- Qualisud, Univ Montpellier, CIRAD, Montpellier SupAgro, Univ d'Avignon, Univ de La Réunion, Montpellier, France; CIRAD, UMR Qualisud, F-34398, Montpellier, France
| | - S Guendouz
- MGX, Biocampus Montpellier, CNRS, INSERM, Univ Montpellier, Montpellier, France
| | - M Pratlong
- MGX, Biocampus Montpellier, CNRS, INSERM, Univ Montpellier, Montpellier, France
| | - A Fontana
- Qualisud, Univ Montpellier, CIRAD, Montpellier SupAgro, Univ d'Avignon, Univ de La Réunion, Montpellier, France
| | - S Schorr-Galindo
- Qualisud, Univ Montpellier, CIRAD, Montpellier SupAgro, Univ d'Avignon, Univ de La Réunion, Montpellier, France.
| |
Collapse
|
29
|
Untch M, Geyer C, Huang C, Loibl S, Wolmark N, Mano M, von Minckwitz G, Brufsky A, Pivot X, Polikoff J, Fontana A, Kaufman B, Alcedo J, Boulet T, Liu H, Song C, Mamounas E. Peripheral neuropathy (PN), thrombocytopenia (TCP) and central nervous system (CNS) recurrence: An update of the phase III KATHERINE trial of post-neoadjuvant trastuzumab emtansine (T-DM1) or trastuzumab (H) in patients (pts) with residual invasive HER2-positive breast cancer (BC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz446.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
30
|
Untch M, Geyer C, Huang C, Loibl S, Wolmark N, Mano M, von Minckwitz G, Brufsky A, Pivot X, Polikoff J, Fontana A, Kaufman B, Alcedo J, Boulet T, Liu H, Song C, Mamounas E. Peripheral neuropathy (PN), thrombocytopenia (TCP) and central nervous system (CNS) recurrence: An update of the phase III KATHERINE trial of post-neoadjuvant trastuzumab emtansine (T-DM1) or trastuzumab (H) in patients (pts) with residual invasive HER2-positive breast cancer (BC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz394.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Sbrana A, Paolieri F, Sammarco E, Bloise F, Zucchelli G, Massa V, Lorenzini G, Borelli B, Boccaccino A, Catanese S, Pecora I, Galli L, Fontana A, Falcone A, Antonuzzo A. Clinical benefit from late lines of therapy offered to patients treated in a tertiary referral centre. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz265.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
32
|
Cazzaniga ME, Pinotti G, Montagna E, Amoroso D, Berardi R, Butera A, Cagossi K, Cavanna L, Ciccarese M, Cinieri S, Cretella E, De Conciliis E, Febbraro A, Ferraù F, Ferzi A, Fiorentini G, Fontana A, Gambaro AR, Garrone O, Gebbia V, Generali D, Gianni L, Giovanardi F, Grassadonia A, Leonardi V, Marchetti P, Melegari E, Musolino A, Nicolini M, Putzu C, Riccardi F, Santini D, Saracchini S, Sarobba MG, Schintu MG, Scognamiglio G, Spadaro P, Taverniti C, Toniolo D, Tralongo P, Turletti A, Valenza R, Valerio MR, Vici P, Clivio L, Torri V. Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study. Breast 2019; 48:7-16. [PMID: 31470257 DOI: 10.1016/j.breast.2019.07.006] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2019] [Revised: 07/24/2019] [Accepted: 07/29/2019] [Indexed: 12/21/2022] Open
Abstract
Metronomic chemotherapy (mCHT) refers to the minimum biologically effective dose of a chemotherapy agent given as a continuous dosing regimen, with no prolonged drug-free breaks, that leads to antitumor activity. Aim of the present study is to describe the use of mCHT in a retrospective cohort of metastatic breast cancer (MBC) patients in order to collect data regarding the different types and regimens of drugs employed, their efficacy and safety. Between January 2011 and December 2016, data of 584 metastatic breast cancer patients treated with mCHT were collected. The use of VRL-based regimens increased during the time of observation (2011: 16.8% - 2016: 29.8%), as well as CTX-based ones (2011: 17.1% - 2016: 25.6%), whereas CAPE-based and MTX-based regimens remained stable. In the 1st-line setting, the highest ORR and DCR were observed for VRL-based regimens (single agent: 44% and 88%; combination: 36.7% and 82.4%, respectively). Assuming VRL-single agent as the referee treatment (median PFS: 7.2 months, 95% CI: 5.3-10.3), the longest median PFS were observed in VRL-combination regimens (9.5, 95%CI 88.8-11.3, HR = 0.72) and in CAPE-single agent (10.7, 95%CI 8.3-15.8, HR = 0.70). The VICTOR-6 study provides new data coming from the real-life setting, by adding new information regarding the use of mCHT as an option of treatment for MBC patients.
Collapse
Affiliation(s)
- M E Cazzaniga
- Research Unit Phase I Trials, ASST Monza, Monza, Italy; Oncology Unit, ASST Monza, Italy.
| | - G Pinotti
- Medical Oncology, ASST Sette Laghi "Ospedale di Circolo e Fondazione Macchi, Varese, VA, Italy
| | - E Montagna
- Medical Senology Division, IEO, Milan, Italy
| | - D Amoroso
- Medical Oncology, Ospedale Della Versilia, Lido di Camaiore, IT, Italy
| | - R Berardi
- Medical Oncology, A. Ospedaliero-universitaria Ospedali Riuniti, Ancona, IT, Italy
| | - A Butera
- Medical Oncology, Ospedale San Giovanni di Dio, Agrigento, IT, Italy
| | - K Cagossi
- Medical Oncology, Ospedale Ramazzini, Carpi, IT, Italy
| | - L Cavanna
- Medical Oncology, Azienda Ospedaliera Piacenza, Piacenza, IT, Italy
| | - M Ciccarese
- Medical Oncology, Ospedale Vito Fazzi, Lecce, IT, Italy
| | - S Cinieri
- Medical Oncology, ASL Brindisi, Brindisi, Italy
| | - E Cretella
- Medical Oncology, Ospedale Bolzano, IT, Italy
| | | | - A Febbraro
- Medical Oncology, Ospedale S. Cuore di Gesù Fatebenefratelli, Benevento, Italy
| | - F Ferraù
- Medical Oncology, Osp Taormina, Taormina, IT, Italy
| | - A Ferzi
- Medical Oncology, A.S.S.T. Ovest Milanese, Legnano, IT, Italy
| | - G Fiorentini
- Medical Oncology, Ospedale San Salvatore, Pesaro, Italy
| | - A Fontana
- Medical Oncology, Az. Ospedaliero-Universitaria, Pisana, IT, Italy
| | - A R Gambaro
- Medical Oncology, ASST Fatebenefratelli, Sacco, IT, Italy
| | - O Garrone
- Medical Oncology, A.O. S. Croce e Carle, Cuneo, Italy
| | - V Gebbia
- Medical Oncology, Ospedale La Maddalena, Palermo, IT, Italy
| | - D Generali
- Medical Oncology, Istituti Ospitalieri Cremona, Cremona, IT, Italy
| | - L Gianni
- Medical Oncology, Azienda USL Romagna, U.O. di Oncologia Rimini, Cattolica, IT, Italy
| | - F Giovanardi
- Medical Oncology, Ospedale Civile, Guastalla, IT, Italy
| | - A Grassadonia
- Medical Oncology, P.O. SS Annunziata -ASL2 Lanciano-Vasto, Chieti, IT, Italy
| | - V Leonardi
- Medical Oncology, Ospedale Civico, Palermo, IT, Italy
| | - P Marchetti
- Medical Oncology, A.O. Sant'Andrea, Roma, IT, Italy
| | - E Melegari
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - A Musolino
- Medical Oncology, Azienda Ospedaliero-Universitaria di Parma, IT, Italy
| | - M Nicolini
- Medical Oncology, Azienda USL Romagna, U.O. di Oncologia Rimini, Cattolica, IT, Italy
| | - C Putzu
- Medical Oncology, A. Ospedaliera-Universitaria, Sassari, IT, Italy
| | - F Riccardi
- Medical Oncology, A. Ospedaliera Antonio Cardarelli, Napoli, IT, Italy
| | - D Santini
- Medical Oncology Università Campus Bio-Medico, Roma, IT, Italy
| | - S Saracchini
- Medical Oncology, Az. Osp. Santa Maria Degli Angeli, Pordenone, IT, Italy
| | - M G Sarobba
- Medical Oncology, Ospedale San Francesco, Nuoro, IT, Italy
| | - M G Schintu
- Medical Oncology, Osp Giovanni Paolo II, Olbia, IT, Italy
| | | | - P Spadaro
- Medical Oncology, Casa di Cura Villa Salus, Messina, IT, Italy
| | - C Taverniti
- Medical Oncology, A.O.U. Città Della Salute e Della Scienza, Osp. Molinette, Torino, IT, Italy
| | - D Toniolo
- Medical Oncology, ASST Rhodense 3 Ospedale di Circolo Rho, IT, Italy
| | - P Tralongo
- Medical Oncology, Osp. Umberto I, Siracusa, IT, Italy
| | - A Turletti
- Medical Oncology, P.O. Martini, Torino, IT, Italy
| | - R Valenza
- Medical Oncology, P.O. Vittorio Emanuele, Gela, IT, Italy
| | - M R Valerio
- Medical Oncology, A.O.U. Policlinico Paolo Giaccone, Palermo, IT, Italy
| | - P Vici
- Medical Oncology, B, INT Regina Elena, Roma, IT, Italy
| | - L Clivio
- Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Italy
| | - V Torri
- Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Italy
| | | |
Collapse
|
33
|
Fioruzzi A, Acerbi A, Jannelli E, Ivone A, Fontana A. Interobserver and intraobserver reliability of a new radiological classification for femoroacetabular impingement syndrome. Musculoskelet Surg 2019; 104:279-284. [PMID: 31363929 DOI: 10.1007/s12306-019-00618-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2019] [Accepted: 07/25/2019] [Indexed: 02/08/2023]
Abstract
PURPOSE Radiological evaluation of femoroacetabular impingement is based on single-plane parameters such as the alpha angle or the center edge angle, or complex software reconstruction. A new simple classification for cam and pincer morphologies, based on a two-plane radiological evaluation, is presented in this study. The determination of the intraobserver and interobserver reliability of this new classification is the purpose of this study. METHODS We retrospectively reviewed the three-view hip study in patient undergoing hip arthroscopy for FAI syndrome between October 2015 and April 2016. Any case having protrusio acetabuli, coxa profunda or which has undergone previous osteotomic surgery was excluded. Five observers used our proposed classification to identify three different stages for the cam and pincer morphologies. Inter- and intraobserver agreement of classification was determined using average pairwise Cohen's kappa coefficient. RESULTS The interobserver agreement for the pincer and cam morphologies was excellent. For the pincer morphology classification, the average Kappa agreement was 0.838 (range 0.764-0.944). For the cam morphology, the average pairwise Cohen's kappa coefficient was 0.846 (range 0.734-0.929). The intraobserver agreement was excellent as well. The average percent pairwise agreement was 0.870 and 0.845 for pincer and cam type, respectively. CONCLUSIONS The new classification system shows excellent levels of inter- and intraobserver agreement for both deformities. This classification is demonstrated to be a useful tool in planning hip arthroscopy. Further studies are needed to correlate the classification itself with specific intraoperative findings.
Collapse
Affiliation(s)
- A Fioruzzi
- Hip Department, Orthopedics and Trauma, IRCCS Policlinico San Donato, Piazza Edmondo Malan 2, 20097, San Donato Milanese, Milan, Italy.
| | - A Acerbi
- C.O.F. Lanzo Hospital, Como, Italy
| | - E Jannelli
- Clinica di Ortopedia e Traumatologia, Fondazione IRCCS Policlinico San Matteo, Università degli Studi di Pavia, Pavia, Italy
| | - A Ivone
- Clinica di Ortopedia e Traumatologia, Fondazione IRCCS Policlinico San Matteo, Università degli Studi di Pavia, Pavia, Italy
| | | |
Collapse
|
34
|
Agosta F, Spinelli EG, Riva N, Fontana A, Basaia S, Canu E, Castelnovo V, Falzone Y, Carrera P, Comi G, Filippi M. Survival prediction models in motor neuron disease. Eur J Neurol 2019; 26:1143-1152. [PMID: 30920076 DOI: 10.1111/ene.13957] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2018] [Accepted: 03/18/2019] [Indexed: 11/29/2022]
Abstract
BACKGROUND AND PURPOSE This study aimed to assess the predictive value of multimodal brain magnetic resonance imaging (MRI) on survival in a large cohort of patients with motor neuron disease (MND), in combination with clinical and cognitive features. METHODS Two hundred MND patients were followed up prospectively for a median of 4.13 years. At baseline, subjects underwent neurological examination, cognitive assessment and brain MRI. Grey matter volumes of cortical and subcortical structures and diffusion tensor MRI metrics of white matter tracts were obtained. A multivariable Royston-Parmar survival model was created using clinical and cognitive variables. The increase of survival prediction accuracy provided by MRI variables was assessed. RESULTS The multivariable clinical model included predominant upper or lower motor neuron presentations and diagnostic delay as significant prognostic predictors, reaching an area under the receiver operating characteristic curve (AUC) of a 4-year survival prediction of 0.79. The combined clinical and MRI model including selected grey matter fronto-temporal volumes and diffusion tensor MRI metrics of the corticospinal and extra-motor tracts reached an AUC of 0.89. Considering amyotrophic lateral sclerosis patients only, the clinical model including diagnostic delay and semantic fluency scores provided an AUC of 0.62, whereas the combined clinical and MRI model reached an AUC of 0.77. CONCLUSION Our study demonstrated that brain MRI measures of motor and extra-motor structural damage, when combined with clinical and cognitive features, are useful predictors of survival in patients with MND, particularly when a diagnosis of amyotrophic lateral sclerosis is made.
Collapse
Affiliation(s)
- F Agosta
- Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy
| | - E G Spinelli
- Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy
| | - N Riva
- Department of Neurology, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy
| | - A Fontana
- Unit of Biostatistics, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy
| | - S Basaia
- Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy
| | - E Canu
- Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy
| | - V Castelnovo
- Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy
| | - Y Falzone
- Department of Neurology, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy
| | - P Carrera
- Unit of Genomics for Human Disease Diagnosis, Division of Genetics and Cell Biology, Clinical Molecular Biology Laboratory, San Raffaele Scientific Institute, Milan, Italy
| | - G Comi
- Department of Neurology, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy
| | - M Filippi
- Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.,Department of Neurology, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy
| |
Collapse
|
35
|
Di Profio P, Germani R, Fontana A, Canale V. Surface charge modulation of sulfobetaine micelles by interaction with different anions: A dynamic light scattering study. J Mol Liq 2019. [DOI: 10.1016/j.molliq.2019.01.075] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|
36
|
Affiliation(s)
- A. Fontana
- Orthopaedic Unit, COF Lanzo Hospital, Ramponio Verna (CO), Italy
| |
Collapse
|
37
|
Fioruzzi A, Jannelli E, Iovone A, Perrelli S, Fontana A, Giai Via A. Arthroscopic management of anterior inferior iliac spine impingement: a systematic review. Muscles Ligaments Tendons J 2019. [DOI: 10.32098/mltj.02.2018.06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- A. Fioruzzi
- Clinica ortopedica e traumatologica, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - E. Jannelli
- Clinica ortopedica e traumatologica, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - A. Iovone
- Clinica ortopedica e traumatologica, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - S. Perrelli
- Clinica ortopedica e traumatologica, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - A. Fontana
- Ortopedia 1, COF Lanzo Hospital, Lanzo d'Intelvi (CO), Italy
| | - A. Giai Via
- Department of Orthopaedics and Traumatology, Hip Surgery Center, IRCCS Policlinico San Donato, Milan, Italy
| |
Collapse
|
38
|
Intiso D, Fontana A, Copetti M, Di Rienzo F. Serum vitamin D deficiency in subjects with severe acquired brain injury and relationship with functional severity. Brain Inj 2018; 32:1817-1823. [PMID: 30339483 DOI: 10.1080/02699052.2018.1537512] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
BACKGROUND Vitamin D may be important for the development and function of the nervous system. Low serum vitamin D levels have been detected in several neurological diseases. OBJECTIVE To ascertain the relationship between 25(OH)D serum level and disability in subjects with severe acquired brain injury (sABI). DESIGN Prospective cross-sectional study Methods: Consecutive subjects with sABI admitted to neuro-rehabilitation were enrolled. A sample of subjects from the neurological ward was considered the control group. Vitamin D serum levels and blood parameters were measured at admission. Disability Rating Scale (DRS), Glasgow Outcome Scale (GOS), and Level of Cognitive Functioning (LCF) were used in assessing disability. RESULTS A total of 104 subjects (34 F, 70 M; mean age 53.9 ± 15.2 years) were enrolled: 54 (19 F, 35 M) with sABI and 50 (15 F, 35 M) subjects as control group. Deficient mean serum levels of vitamin D (19.2 ± 9.4 ng/mL) were detected in the subjects with sABI and a significant inverse correlation between vitamin D serum levels and DRS score was detected (p = 0.04). CONCLUSION Subjects with sABI showed vitamin D deficiency that might correlate to disability severity. The reason is unclear and might represent a secondary phenomenon resulting from the inflammatory process.
Collapse
Affiliation(s)
- D Intiso
- a Unit of Neuro-rehabilitation, and Rehabilitation Medicine , IRCCS "Casa Sollievo della Sofferenza" , San Giovanni Rotondo , Foggia , Italy
| | - A Fontana
- b Unit of Biostatistics , IRCCS "Casa Sollievo della Sofferenza" , San Giovanni Rotondo , Foggia , Italy
| | - M Copetti
- b Unit of Biostatistics , IRCCS "Casa Sollievo della Sofferenza" , San Giovanni Rotondo , Foggia , Italy
| | - F Di Rienzo
- a Unit of Neuro-rehabilitation, and Rehabilitation Medicine , IRCCS "Casa Sollievo della Sofferenza" , San Giovanni Rotondo , Foggia , Italy
| |
Collapse
|
39
|
Conte B, Fabi A, Poggio F, Blondeaux E, Dellepiane C, D'Alonzo A, Staiano A, Buono G, Arpino G, Magri V, Naso G, Presti D, Mura S, Fontana A, Cognetti F, Molinelli C, Pastorino S, Bighin C, Lambertini M, Del Mastro L. Effectiveness of trastuzumab emtansine (TDM1) in patients with HER2-positive advanced breast cancer (ABC) progressing after taxane plus pertuzumab plus trastuzumab. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy272.316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Crucitta S, Del Re M, Fontana A, Bertolini I, Rofi E, De Angelis C, Diodati L, Cavallero D, Salvadori B, Falcone A, Morganti R, Danesi R. Expression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical response to CDK4/6 inhibitors in breast cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy269.143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
41
|
Durand N, Fontana A, Meile JC, Suàrez-Quiroz ML, Schorr-Galindo S, Montet D. Differentiation and quantification of the ochratoxin A producers Aspergillus ochraceus and Aspergillus westerdijkiae using PCR-DGGE. J Basic Microbiol 2018; 59:158-165. [PMID: 30240041 DOI: 10.1002/jobm.201800172] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2018] [Revised: 08/29/2018] [Accepted: 09/01/2018] [Indexed: 11/11/2022]
Abstract
Ochratoxin A (OTA) is a nephrotoxic, teratogenic, immunotoxic, and carcinogenic mycotoxin which is produced in tropical zones mainly by Aspergillus carbonarius, A. niger, A. ochraceus, and A. westerdijkiae. A. ochraceus and A. westerdijkiae species are phenotypically and genomically very close but A. westerdijkiae produce OTA at a very higher level than A. ochraceus. These species have been differentiated recently. The DNA primer pairs which were drawn so far are not specific and a genomic region of the same size is amplified for both species or they are too specific, and in this case, the DNA of a single species is amplified. To help preventing OTA contamination of foodstuffs, the PCR-DGGE (Denaturing Gradient Gel Electrophoresis) method was used to discriminate between A. ochraceus and A. westerdijkiae DNA fragments of the same size but with different sequences and thus faster access to a diagnosis of the toxigenic potential of the fungal microflora. The proposed methodology was able to differentiate A. westerdijkiae from A. ochraceus with only one primer pairs in a single run. A calibration based on initial DNA content was obtained from image analysis of the DGGE gels and a method of quantification of the two strains was proposed.
Collapse
Affiliation(s)
- Noël Durand
- Qualisud, Univ Montpellier, CIRAD, Montpellier SupAgro, Univ d'Avignon, Univ de La Réunion, Montpellier, France
| | - Angélique Fontana
- Qualisud, Univ Montpellier, CIRAD, Montpellier SupAgro, Univ d'Avignon, Univ de La Réunion, Montpellier, France
| | - Jean-Christophe Meile
- Qualisud, Univ Montpellier, CIRAD, Montpellier SupAgro, Univ d'Avignon, Univ de La Réunion, Montpellier, France
| | | | - Sabine Schorr-Galindo
- Qualisud, Univ Montpellier, CIRAD, Montpellier SupAgro, Univ d'Avignon, Univ de La Réunion, Montpellier, France
| | - Didier Montet
- Qualisud, Univ Montpellier, CIRAD, Montpellier SupAgro, Univ d'Avignon, Univ de La Réunion, Montpellier, France
| |
Collapse
|
42
|
Burocchi S, Gori M, Cioffi G, Calabrese A, Canova P, De Maria R, Grosu A, Fontana A, Iacovoni A, Ferrari P, Volpe M, Gavazzi A, Senni M. P5661Influence of midwall fractional shortening on incident heart failure and death in asymptomatic subjects at high risk of events. Insights from the DAVID-Berg study. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p5661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- S Burocchi
- Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - M Gori
- Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - G Cioffi
- Villa Bianca Hospital, Trento, Italy
| | - A Calabrese
- Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - P Canova
- Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - R De Maria
- Niguarda Ca' Granda Hospital, Milan, Italy
| | - A Grosu
- Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - A Fontana
- Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - A Iacovoni
- Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - P Ferrari
- Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - M Volpe
- Sant' Andrea Hospital, Rome, Italy
| | - A Gavazzi
- FROM Research Foundation, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy
| | - M Senni
- Ospedale Papa Giovanni XXIII, Bergamo, Italy
| |
Collapse
|
43
|
Canale V, Germani R, Siani G, Fontana A, Di Profio P. Fractional ionization and size of cetyltrialkyl ammonium bromide and hydroxide micelles as a function of head-group lipophilicity and temperature. J Mol Liq 2018. [DOI: 10.1016/j.molliq.2018.04.090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
44
|
Waré LY, Nikièma AP, Meile JC, Kaboré S, Fontana A, Durand N, Montet D, Barro N. Microbiological safety of flours used in follow up for infant formulas produced in Ouagadougou, Burkina Faso. AIMS Microbiol 2018; 4:347-361. [PMID: 31294220 PMCID: PMC6604933 DOI: 10.3934/microbiol.2018.2.347] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2018] [Accepted: 05/02/2018] [Indexed: 11/18/2022] Open
Abstract
The prevalence of diarrheal diseases in children aged from 6 to 24 months in Burkina Faso is 38%. These diarrheas may be due to the consumption of contaminated weaning food. Therefore, the microbiological quality of follow up infant flours used as supplement foods is a key-point to reduce children diseases. In this study, the microbiological safety of locally-produced infant flours was investigated. One hundred and ninety-nine (199) samples were collected mainly in retails outlets and in Recovery and Nutrition Education Centers. According to the Burkina Faso regulations, microbiological analyses were carried out for Total Aerobic Mesophilic Flora (TAMF), thermotolerant coliforms, Salmonella spp. and yeasts/molds. The bacterial and fungal isolates were identified using phenotypic and genotypic methods and the study of the production of mycotoxins was carried out from the fungal isolates. In collected samples, the TAMF count ranged from 0 to 1.8 × 106 CFU/g with a total average of 6.3 × 104 CFU/g. About 2% of the samples had a microbial load exceeding the standards (105 CFU/g). No Salmonella spp. was isolated in the final infant flours. However, the presence of Enterobacteriaceae (Klebsiella spp. Enterobacter spp. and Cronobacter spp.) was detected and molecular characterization revealed also the presence of fungal species of the genus Aspergillus spp., Penicillium spp. and Fusarium spp. Some of these species were found to produce aflatoxins, ochratoxin A and fumonisins, which are potential carcinogenic toxins. These results demonstrated the need for a preventive approach based on the application of Hazard Analysis Critical Control Point in the food industry to ensure food safety of infant flours in Burkina Faso.
Collapse
Affiliation(s)
- Larissa Y Waré
- Laboratory of Molecular Biology, Epidemiology and Surveillance of Bacteria and Viruses Transmitted by Food (LaBESTA), Center for Research in Biological Sciences, Food and Nutrition (CRSBAN), Doctoral School Sciences and Technologies, University of Ouaga I Pr JOSEPH KI-ZERBO, Burkina Faso
| | - Augustini P Nikièma
- Laboratory of Molecular Biology, Epidemiology and Surveillance of Bacteria and Viruses Transmitted by Food (LaBESTA), Center for Research in Biological Sciences, Food and Nutrition (CRSBAN), Doctoral School Sciences and Technologies, University of Ouaga I Pr JOSEPH KI-ZERBO, Burkina Faso
| | - Jean C Meile
- CIRAD, UMR Qualisud, F-34398 Montpellier, France.,Qualisud, University of Montpellier, CIRAD, Montpellier SupAgro, University of Avignon, University of Reunion, Montpellier, France
| | - Saïdou Kaboré
- Laboratory of Molecular Biology, Epidemiology and Surveillance of Bacteria and Viruses Transmitted by Food (LaBESTA), Center for Research in Biological Sciences, Food and Nutrition (CRSBAN), Doctoral School Sciences and Technologies, University of Ouaga I Pr JOSEPH KI-ZERBO, Burkina Faso
| | - Angélique Fontana
- Qualisud, University of Montpellier, CIRAD, Montpellier SupAgro, University of Avignon, University of Reunion, Montpellier, France
| | - Noël Durand
- CIRAD, UMR Qualisud, F-34398 Montpellier, France.,Qualisud, University of Montpellier, CIRAD, Montpellier SupAgro, University of Avignon, University of Reunion, Montpellier, France
| | - Didier Montet
- CIRAD, UMR Qualisud, F-34398 Montpellier, France.,Qualisud, University of Montpellier, CIRAD, Montpellier SupAgro, University of Avignon, University of Reunion, Montpellier, France
| | - Nicolas Barro
- Laboratory of Molecular Biology, Epidemiology and Surveillance of Bacteria and Viruses Transmitted by Food (LaBESTA), Center for Research in Biological Sciences, Food and Nutrition (CRSBAN), Doctoral School Sciences and Technologies, University of Ouaga I Pr JOSEPH KI-ZERBO, Burkina Faso
| |
Collapse
|
45
|
Doser M, Aghion S, Amsler C, Bonomi G, Brusa RS, Caccia M, Caravita R, Castelli F, Cerchiari G, Comparat D, Consolati G, Demetrio A, Di Noto L, Evans C, Fanì M, Ferragut R, Fesel J, Fontana A, Gerber S, Giammarchi M, Gligorova A, Guatieri F, Haider S, Hinterberger A, Holmestad H, Kellerbauer A, Khalidova O, Krasnický D, Lagomarsino V, Lansonneur P, Lebrun P, Malbrunot C, Mariazzi S, Marton J, Matveev V, Mazzotta Z, Müller SR, Nebbia G, Nedelec P, Oberthaler M, Pacifico N, Pagano D, Penasa L, Petracek V, Prelz F, Prevedelli M, Rienaecker B, Robert J, Røhne OM, Rotondi A, Sandaker H, Santoro R, Smestad L, Sorrentino F, Testera G, Tietje IC, Widmann E, Yzombard P, Zimmer C, Zmeskal J, Zurlo N. AEgIS at ELENA: outlook for physics with a pulsed cold antihydrogen beam. Philos Trans A Math Phys Eng Sci 2018; 376:20170274. [PMID: 29459413 PMCID: PMC5829176 DOI: 10.1098/rsta.2017.0274] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 12/05/2017] [Indexed: 06/08/2023]
Abstract
The efficient production of cold antihydrogen atoms in particle traps at CERN's Antiproton Decelerator has opened up the possibility of performing direct measurements of the Earth's gravitational acceleration on purely antimatter bodies. The goal of the AEgIS collaboration is to measure the value of g for antimatter using a pulsed source of cold antihydrogen and a Moiré deflectometer/Talbot-Lau interferometer. The same antihydrogen beam is also very well suited to measuring precisely the ground-state hyperfine splitting of the anti-atom. The antihydrogen formation mechanism chosen by AEgIS is resonant charge exchange between cold antiprotons and Rydberg positronium. A series of technical developments regarding positrons and positronium (Ps formation in a dedicated room-temperature target, spectroscopy of the n=1-3 and n=3-15 transitions in Ps, Ps formation in a target at 10 K inside the 1 T magnetic field of the experiment) as well as antiprotons (high-efficiency trapping of [Formula: see text], radial compression to sub-millimetre radii of mixed [Formula: see text] plasmas in 1 T field, high-efficiency transfer of [Formula: see text] to the antihydrogen production trap using an in-flight launch and recapture procedure) were successfully implemented. Two further critical steps that are germane mainly to charge exchange formation of antihydrogen-cooling of antiprotons and formation of a beam of antihydrogen-are being addressed in parallel. The coming of ELENA will allow, in the very near future, the number of trappable antiprotons to be increased by more than a factor of 50. For the antihydrogen production scheme chosen by AEgIS, this will be reflected in a corresponding increase of produced antihydrogen atoms, leading to a significant reduction of measurement times and providing a path towards high-precision measurements.This article is part of the Theo Murphy meeting issue 'Antiproton physics in the ELENA era'.
Collapse
Affiliation(s)
- M Doser
- Physics Department, CERN, 1211 Geneva 23, Switzerland
| | - S Aghion
- Politecnico of Milano, Piazza Leonardo da Vinci 32, 20133 Milano, Italy
- INFN Milano, via Celoria 16, 20133 Milano, Italy
| | - C Amsler
- Stefan Meyer Institute for Subatomic Physics, Austrian Academy of Sciences, Boltzmanngasse 3, 1090 Vienna, Austria
| | - G Bonomi
- Department of Mechanical and Industrial Engineering, University of Brescia, via Branze 38, 25123 Brescia, Italy
- INFN Pavia, via Bassi 6, 27100 Pavia, Italy
| | - R S Brusa
- Department of Physics, University of Trento, via Sommarive 14, 38123 Povo, Trento, Italy
- TIFPA/INFN Trento, via Sommarive 14, 38123 Povo, Trento, Italy
| | - M Caccia
- INFN Milano, via Celoria 16, 20133 Milano, Italy
- Department of Science, University of Insubria, via Valleggio 11, 22100 Como, Italy
| | - R Caravita
- Department of Physics, University of Genova, via Dodecaneso 33, 16146 Genova, Italy
- INFN Genova, via Dodecaneso 33, 16146 Genova, Italy
| | - F Castelli
- INFN Milano, via Celoria 16, 20133 Milano, Italy
- Department of Physics, University of Milano, via Celoria 16, 20133 Milano, Italy
| | - G Cerchiari
- Max Planck Institute for Nuclear Physics, Saupfercheckweg 1, 69117 Heidelberg, Germany
| | - D Comparat
- Laboratoire Aimé Cotton, Université Paris-Sud, ENS Cachan, CNRS, Université Paris-Saclay, 91405 Orsay Cedex, France
| | - G Consolati
- Politecnico of Milano, Piazza Leonardo da Vinci 32, 20133 Milano, Italy
- INFN Milano, via Celoria 16, 20133 Milano, Italy
| | - A Demetrio
- Kirchhoff-Institute for Physics, Heidelberg University, Im Neuenheimer Feld 227, 69120 Heidelberg, Germany
| | - L Di Noto
- Department of Physics, University of Genova, via Dodecaneso 33, 16146 Genova, Italy
- INFN Genova, via Dodecaneso 33, 16146 Genova, Italy
| | - C Evans
- Politecnico of Milano, Piazza Leonardo da Vinci 32, 20133 Milano, Italy
- INFN Milano, via Celoria 16, 20133 Milano, Italy
| | - M Fanì
- Physics Department, CERN, 1211 Geneva 23, Switzerland
- Department of Physics, University of Genova, via Dodecaneso 33, 16146 Genova, Italy
- INFN Genova, via Dodecaneso 33, 16146 Genova, Italy
| | - R Ferragut
- Politecnico of Milano, Piazza Leonardo da Vinci 32, 20133 Milano, Italy
- INFN Milano, via Celoria 16, 20133 Milano, Italy
| | - J Fesel
- Physics Department, CERN, 1211 Geneva 23, Switzerland
| | - A Fontana
- INFN Pavia, via Bassi 6, 27100 Pavia, Italy
| | - S Gerber
- Physics Department, CERN, 1211 Geneva 23, Switzerland
| | - M Giammarchi
- INFN Milano, via Celoria 16, 20133 Milano, Italy
| | - A Gligorova
- Stefan Meyer Institute for Subatomic Physics, Austrian Academy of Sciences, Boltzmanngasse 3, 1090 Vienna, Austria
| | - F Guatieri
- Department of Physics, University of Trento, via Sommarive 14, 38123 Povo, Trento, Italy
- TIFPA/INFN Trento, via Sommarive 14, 38123 Povo, Trento, Italy
| | - S Haider
- Physics Department, CERN, 1211 Geneva 23, Switzerland
| | | | - H Holmestad
- Department of Physics, University of Oslo, Sem Slandsvei 24, 0371 Oslo, Norway
| | - A Kellerbauer
- Max Planck Institute for Nuclear Physics, Saupfercheckweg 1, 69117 Heidelberg, Germany
| | - O Khalidova
- Physics Department, CERN, 1211 Geneva 23, Switzerland
| | - D Krasnický
- INFN Genova, via Dodecaneso 33, 16146 Genova, Italy
| | - V Lagomarsino
- Department of Physics, University of Genova, via Dodecaneso 33, 16146 Genova, Italy
- INFN Genova, via Dodecaneso 33, 16146 Genova, Italy
| | - P Lansonneur
- Institute of Nuclear Physics, CNRS/IN2p3, University of Lyon 1, 69622 Villeurbanne, France
| | - P Lebrun
- Institute of Nuclear Physics, CNRS/IN2p3, University of Lyon 1, 69622 Villeurbanne, France
| | - C Malbrunot
- Physics Department, CERN, 1211 Geneva 23, Switzerland
- Stefan Meyer Institute for Subatomic Physics, Austrian Academy of Sciences, Boltzmanngasse 3, 1090 Vienna, Austria
| | - S Mariazzi
- INFN Padova, via Marzolo 8, 35131 Padova, Italy
| | - J Marton
- Stefan Meyer Institute for Subatomic Physics, Austrian Academy of Sciences, Boltzmanngasse 3, 1090 Vienna, Austria
| | - V Matveev
- Institute for Nuclear Research of the Russian Academy of Science, Moscow 117312, Russia
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
| | - Z Mazzotta
- INFN Milano, via Celoria 16, 20133 Milano, Italy
- Department of Physics, University of Milano, via Celoria 16, 20133 Milano, Italy
| | - S R Müller
- Kirchhoff-Institute for Physics, Heidelberg University, Im Neuenheimer Feld 227, 69120 Heidelberg, Germany
| | - G Nebbia
- INFN Padova, via Marzolo 8, 35131 Padova, Italy
| | - P Nedelec
- Institute of Nuclear Physics, CNRS/IN2p3, University of Lyon 1, 69622 Villeurbanne, France
| | - M Oberthaler
- Kirchhoff-Institute for Physics, Heidelberg University, Im Neuenheimer Feld 227, 69120 Heidelberg, Germany
| | - N Pacifico
- Physics Department, CERN, 1211 Geneva 23, Switzerland
| | - D Pagano
- Department of Mechanical and Industrial Engineering, University of Brescia, via Branze 38, 25123 Brescia, Italy
- INFN Pavia, via Bassi 6, 27100 Pavia, Italy
| | - L Penasa
- Department of Physics, University of Trento, via Sommarive 14, 38123 Povo, Trento, Italy
- TIFPA/INFN Trento, via Sommarive 14, 38123 Povo, Trento, Italy
| | - V Petracek
- Czech Technical University in Prague, Brehová 7, 11519 Prague 1, Czech Republic
| | - F Prelz
- INFN Milano, via Celoria 16, 20133 Milano, Italy
| | - M Prevedelli
- University of Bologna, Viale Berti Pichat 6/2, 40126 Bologna, Italy
| | - B Rienaecker
- Physics Department, CERN, 1211 Geneva 23, Switzerland
| | - J Robert
- Laboratoire Aimé Cotton, Université Paris-Sud, ENS Cachan, CNRS, Université Paris-Saclay, 91405 Orsay Cedex, France
| | - O M Røhne
- Department of Physics, University of Oslo, Sem Slandsvei 24, 0371 Oslo, Norway
| | - A Rotondi
- INFN Pavia, via Bassi 6, 27100 Pavia, Italy
- Department of Physics, University of Pavia, via Bassi 6, 27100 Pavia, Italy
| | - H Sandaker
- Department of Physics, University of Oslo, Sem Slandsvei 24, 0371 Oslo, Norway
| | - R Santoro
- INFN Milano, via Celoria 16, 20133 Milano, Italy
- Department of Science, University of Insubria, via Valleggio 11, 22100 Como, Italy
| | - L Smestad
- Physics Department, CERN, 1211 Geneva 23, Switzerland
- The Research Council of Norway, PO Box 564, 1327 Lysaker, Norway
| | - F Sorrentino
- INFN Genova, via Dodecaneso 33, 16146 Genova, Italy
| | - G Testera
- INFN Genova, via Dodecaneso 33, 16146 Genova, Italy
| | - I C Tietje
- Physics Department, CERN, 1211 Geneva 23, Switzerland
| | - E Widmann
- Stefan Meyer Institute for Subatomic Physics, Austrian Academy of Sciences, Boltzmanngasse 3, 1090 Vienna, Austria
| | - P Yzombard
- Max Planck Institute for Nuclear Physics, Saupfercheckweg 1, 69117 Heidelberg, Germany
| | - C Zimmer
- Physics Department, CERN, 1211 Geneva 23, Switzerland
- Max Planck Institute for Nuclear Physics, Saupfercheckweg 1, 69117 Heidelberg, Germany
- Department of Physics, Heidelberg University, Im Neuenheimer Feld 226, 69120 Heidelberg, Germany
| | - J Zmeskal
- Stefan Meyer Institute for Subatomic Physics, Austrian Academy of Sciences, Boltzmanngasse 3, 1090 Vienna, Austria
| | - N Zurlo
- INFN Pavia, via Bassi 6, 27100 Pavia, Italy
- Department of Civil Engineering, University of Brescia, via Branze 43, 25123 Brescia, Italy
| |
Collapse
|
46
|
Guatieri F, Aghion S, Amsler C, Angela G, Bonomi G, Brusa R, Caccia M, Caravita R, Castelli F, Cerchiari G, Comparat D, Consolati G, Demetrio A, Di Noto L, Doser M, Evans C, Fanì M, Ferragut R, Fesel J, Fontana A, Gerber S, Giammarchi M, Gligorova A, Haider S, Hinterberger A, Holmestad H, Kellerbauer A, Krasnický D, Lagomarsino V, Lansonneur P, Lebrun P, Malbrunot C, Mariazzi S, Matveev V, Mazzotta Z, Müller S, Nebbia G, Nedelec P, Oberthaler M, Pacifico N, Pagano D, Penasa L, Petracek V, Prelz F, Prevedelli M, Rienaecker B, Robert J, Rhne. O, Rotondi A, Sacerdoti M, Sandaker H, Santoro R, Simon M, Smestad L, Sorrentino F, Testera G, Tietje I, Widmann E, Yzombard P, Zimmer C, Zmeskal J, Zurlo N. AEg̅IS latest results. EPJ Web of Conferences 2018. [DOI: 10.1051/epjconf/201718101037] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
The validity of the Weak Equivalence Principle (WEP) as predicted by General Relativity has been tested up to astounding precision using ordinary matter. The lack hitherto of a stable source of a probe being at the same time electrically neutral, cold and stable enough to be measured has prevented highaccuracy testing of the WEP on anti-matter. The AEg̅IS (Antimatter Experiment: Gravity, Interferometry, Spectroscopy) experiment located at CERN's AD (Antiproton Decelerator) facility aims at producing such a probe in the form of a pulsed beam of cold anti-hydrogen, and at measuring by means of a moiré deflectometer the gravitational force that Earth's mass exerts on it. Low temperature and abundance of the H̅ are paramount to attain a high precision measurement. A technique employing a charge-exchange reaction between antiprotons coming from the AD and excited positronium atoms is being developed at AEg̅IS and will be presented hereafter, alongside an overview of the experimental apparatus and the current status of the experiment
Collapse
|
47
|
Evans C, Aghion S, Amsler C, Bonomi G, Brusa R, Caccia M, Caravita R, Castelli F, Cerchiari G, Comparat D, Consolati G, Demetrio A, Di Noto L, Doser M, Fani M, Ferragut R, Fesel J, Fontana A, Gerber S, Giammarchi M, Gligorova A, Guatieri F, Haider S, Hinterberger A, Holmestad H, Kellerbauer A, Khalidova O, Krasnický D, Lagomarsino V, Lansonneur P, Lebrun P, Malbrunot C, Mariazzi S, Marton J, Matveev V, Mazzotta Z, Müller S, Nebbia G, Nedelec P, Oberthaler M, Pacifico N, Pagano D, Penasa L, Petracek V, Prelz F, Prevedelli M, Ravelli L, Rienaecker B, Robert J, Røhne O, Rotondi A, Sandaker H, Santoro R, Smestad L, Sorrentino F, Testera G, Tietje I, Widmann E, Yzombard P, Zimmer C, Zmeskal J, Zurlo N. Towards the first measurement of matter-antimatter gravitational interaction. EPJ Web Conf 2018. [DOI: 10.1051/epjconf/201818202040] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
The AEgIS (Antimatter Experiment: Gravity, Interferometry, Spectroscopy) is a CERN based experiment with the central aim to measure directly the gravitational acceleration of antihydrogen. Antihydrogen atoms will be produced via charge exchange reactions which will consist of Rydberg-excited positronium atoms sent to cooled antiprotons within an electromagnetic trap. The resulting Rydberg antihydrogen atoms will then be horizontally accelerated by an electric field gradient (Stark effect), they will then pass through a moiré deflectometer. The vertical deflection caused by the Earth's gravitational field will test for the first time the Weak Equivalence Principle for antimatter. Detection will be undertaken via a position sensitive detector. Around 103 antihydrogen atoms are needed for the gravitational measurement to be completed. The present status, current achievements and results will be presented, with special attention toward the laser excitation of positronium (Ps) to the n=3 state and the production of Ps atoms in the transmission geometry.
Collapse
|
48
|
Diodati L, De Angelis C, Bertolini I, Montagnani I, Salvadori B, Ferrari P, Fontana A. Prognostic value of lymph node ratio in early breast cancer: a restrospective single institution analysis of clinical-pathological characteristics and outcomes. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx424.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
49
|
Spallanzani A, Gelsomino F, Caputo F, Salati M, Reggiani Bonetti L, Domati F, Andrikou K, Fontana A, Di Emidio K, Baldessari C, Pugliese G, Bettelli S, Luppi G, Cascinu S. The prognostic impact of sidedness across all stages during the last 20 years: the “Modena Cancer Registry” experience. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx422.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
50
|
D' Alonzo A, Bighin C, Puglisi F, Gerratana L, De Laurentis M, Fontana A, Pugliese P, Ferzi A, Montemurro F, Arpino G, Poggio F, Vaglica M, Dellepiane C, Blondeaux E, Benedetta C, Cognetti F, Garrone O, Turletti A, Pastorino S, Del Mastro L. Trends in the choice of first line treatment for hormone - responsive (HR+), human epidermal growth factor receptor - 2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): results of a multicentric Italian observational study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx424] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|